# 1 COVID-19 susceptibility and severity risks in a survey

# 2 of over 500,000 individuals

Spencer C. Knight<sup>\*1</sup>, Shannon R. McCurdy<sup>\*1</sup>, Brooke Rhead<sup>\*1</sup>, Marie V. Coignet<sup>1</sup>, Danny S. 3 Park<sup>1</sup>, Genevieve H.L. Roberts<sup>2</sup>, Nathan D. Berkowitz<sup>1</sup>, Miao Zhang<sup>1</sup>, David Turissini<sup>1</sup>, Karen 4 5 Delgado<sup>2</sup>, Milos Pavlovic<sup>2</sup>, AncestryDNA Science Team<sup>2</sup>, Asher K. Haug Baltzell<sup>2</sup>, Harendra Guturu<sup>1</sup>, Kristin A. Rand<sup>1</sup>, Ahna R. Girshick<sup>1</sup>, Eurie L. Hong<sup>1</sup>, Catherine A. Ball<sup>1</sup> 6 7 8 \*These authors contributed equally to this work. 9 1. AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107 10 2. AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043 11 12 Corresponding Author: Kristin A. Rand, AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA 94107, United States of America (e-mail: kristinmuench@gmail.com) 13 14 15 Word Count: 3,200 16 17 Keywords: COVID-19, Modeling, Genetic Epidemiology, Statistics 18 19 Abbreviations: aOR (adjusted odds ratio), AUC (area under the curve), BMI (body mass index), 20 CI (confidence interval), CDC (U.S. Centers for Disease Control), CKD (chronic kidney disease), 21 COPD (chronic obstructive pulmonary disease), EGA (European Genome-phenome Archive), 22 GWAS (genome-wide association studies), HWF ("How We Feel" study), ICU (intensive care unit), LR (logistic regression), OR (odds ratio), ROC (receiver operating characteristic) 23 24

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

#### 25 ABSTRACT

#### 26 Background

The enormous toll of the COVID-19 pandemic has heightened the urgency of collecting and analyzing population-scale datasets in real time to monitor and better understand the evolving pandemic.

30 Methods

31 The AncestryDNA COVID-19 Study collected self-reported survey data on symptoms, outcomes,

32 risk factors, and exposures for over 563,000 adult individuals in the U.S. in just under four months,

33 including over 4,700 COVID-19 cases as measured by a self-reported positive test.

#### 34 Results

35 We replicated previously reported associations between several risk factors and COVID-19 36 susceptibility and severity outcomes, and additionally found that differences in known exposures 37 accounted for many of the susceptibility associations. A notable exception was elevated 38 susceptibility for males even after adjusting for known exposures and age (adjusted odds ratio 39 [aOR]=1.36,95% confidence interval [CI] = (1.19, 1.55)). We also demonstrated that self-reported 40 data can be used to build accurate risk models to predict individualized COVID-19 susceptibility 41 (area under the curve [AUC]=0.84) and severity outcomes including hospitalization and critical 42 illness (AUC=0.87 and 0.90, respectively). The risk models achieved robust discriminative 43 performance across different age, sex, and genetic ancestry groups within the study.

#### 44 Conclusion

45 The results highlight the value of self-reported epidemiological data to rapidly provide public46 health insights into the evolving COVID-19 pandemic.

# 48 THUMBNAIL

### 49 What is already known on this subject

50	• The COVID-19 pandemic has exacted a historic toll on human lives, healthcare systems
51	and global economies, with over 83 million cases and over 1.8 million deaths worldwide
52	as of January 2021.
53	• COVID-19 risk factors for susceptibility and severity have been extensively investigated
54	by clinical and public health researchers.
55	• Several groups have developed risk models to predict COVID-19 illness outcomes based
56	on known risk factors.
57	
58	What this study adds
59	• We performed association analyses for COVID-19 susceptibility and severity in a large,
60	at-home survey and replicated much of the previous clinical literature.
61	• Associations were further adjusted for known COVID-19 exposures, and we observed
62	elevated positive test odds for males even after adjustment for these known exposures.
63	• We developed risk models and evaluated them across different age, sex, and genetic
64	ancestry cohorts, and showed robust performance across all cohorts in a holdout dataset.
65	• Our results establish large-scale, self-reported surveys as a potential framework for
66	investigating and monitoring rapidly evolving pandemics.
67	
68	

### 70 INTRODUCTION

71 The COVID-19 pandemic has resulted in over 83 million COVID-19 cases and over 1.8 million 72 deaths worldwide [1], including nearly 21 million cases and more than 350,000 deaths in the 73 United States as of early January 2021 [2]. The growing impact of the pandemic intensifies the 74 need for real-time understanding of COVID-19 susceptibility and severity risk factors, not only 75 for public health experts, but also for individuals seeking to assess their own personalized risk. 76 Prior research has indicated that differences in COVID-19 susceptibility are related to age [3], sex-77 dependent immune responses [4], and genetics [5.6], while heightened severity of COVID-19 78 illness is associated with risk factors such as age [3,7–9], sex [4,10–12], genetic factors [13], and 79 underlying health conditions [7,9,10,14,15]. Self-reported survey data, which can easily be 80 collected in the home, afford the opportunity to dynamically monitor the continually evolving 81 pandemic and allow for real-time estimation of individual-level COVID-19 risk [16-19]. 82 Furthermore, self-reported surveys allow for collection of information about known exposures, of 83 which few epidemiological COVID-19 studies have explicitly accounted for in association 84 analyses to date [20].

85

In this paper, we aimed to replicate previous literature and to provide new insight into factors associated with susceptibility and severity of COVID-19 using a large survey cohort of 563,141 AncestryDNA customers who have consented to participate in the AncestryDNA COVID-19 Study [5]. We performed association tests of known or suspected COVID-19 risk factors with one susceptibility and two severity phenotypes and report unadjusted ORs and ORs adjusted for potential confounding factors. We additionally investigated associations of COVID-19 symptoms with susceptibility and severity.

94	We further demonstrate that this type of self-reported dataset can be used to build accurate
95	predictive risk models for COVID-19 susceptibility and severity outcomes. For susceptibility, we
96	designed two models and additionally applied two literature-based models [18] to predict COVID-
97	19 cases among respondents reporting a test result. We also designed models to predict two
98	different COVID-19 severity outcomes based on minimal information about demographics, health
99	conditions, and symptoms: hospitalization due to COVID-19 infection and progression of an
100	infection to a life-threatening critical case among those reporting a positive COVID-19 result [14].
101	To evaluate the potential for generalizability, we assessed performance of all of the risk models
102	across different age, sex and genetic ancestry cohorts.
103	

#### 104 METHODS

#### 105 **Ethics approval**

All data for this research project were from subjects who have provided informed consent to participate in AncestryDNA's Human Diversity Project, as reviewed and approved by our external institutional review board, Advarra (formerly Quorum, IRB approval number: Pro00034516). Advarra operates under ethical principles underlying the involvement of human subjects in research, including the Declaration of Helsinki. All data were de-identified prior to use.

111

#### 112 Survey description

113 Survey responses were collected from AncestryDNA customers consented to research in the U.S. 114 between April 22 and July 6, 2020. The survey consisted of 50+ questions about COVID-19 test 115 results, 15 symptoms among those who tested positive or who tested negative and had flu-like 116 symptoms, disease progression for positive testers, age, height, weight, known exposures to 117 biological relatives, household members, patients or any other contacts with COVID-19, and 11 118 underlying health conditions (Supplementary Tables 1 and 2). Collection of self-reported COVID-119 19 outcomes from U.S. AncestryDNA customers who consented to research for the study, and the 120 survey design are described in more detail in a genome-wide association study (GWAS) on a very 121 similar AncestryDNA dataset [5]. Here, participants reporting a negative test result were also 122 assessed for symptoms and clinical outcomes.

123

#### 124 **Outcome definitions**

The study assessed three outcomes: one for susceptibility and two for severity of COVID-19 infection. Cases for COVID-19 susceptibility were individuals who responded, "Yes, and was positive" to the question, "Have you been swab tested for COVID-19, commonly referred to as coronavirus?" Responders who answered, "Yes, and was negative" were used as controls for the susceptibility analysis.

The hospitalization outcome was defined among COVID-19-positive cases if a participant responded "Yes" to a binary question about experiencing symptoms due to COVID-19 illness and "Yes" to the hospitalization question ("Were you hospitalized due to these symptoms?). Controls were defined by a response of "No" to the symptoms question or a response of "No" to the hospitalization question in addition to reporting a self-reported positive COVID-19 test result [5].

135

136 Critical cases of COVID-19 were defined via a response of "Yes" to one or more questions about 137 ICU admittance or, alternatively, self-reported septic shock, organ failure, or respiratory failure 138 resulting from a COVID-19 infection [14]. Controls were defined by a response of "No" across 139 all of these questions in addition to self-reporting a positive COVID-19 test result.

140

#### 141 Genetic sex and ancestry definitions

All individuals were genotyped, using previously described general genotyping and quality control procedures [21]. Both sex and genetic ancestry were defined for individuals based on their genotypes. Genetic ancestry was estimated using a proprietary algorithm to estimate continental admixture proportions [22]. All participants were assigned to one of four broad genetic ancestry groups: European ancestry, admixed African-European ancestry, admixed Amerindian ancestry, or other ancestry combinations.

#### 149 **Data preparation for analysis**

150 Multiple-choice categorical questions were one-hot ("dummy") encoded as binary risk factors.

We considered several risk factors and outcomes questions in our association analyses and risk 152 modeling efforts, some of which are summarized in Supplementary Tables 1 and 2. Based on the 153 dependency structure of the survey, we made the following inferences:

154

151

155 Participants reporting "No" to a binary question about symptoms arising from COVID-19 156 infection were designated as negatives for dependent questions about individual symptoms, 157 hospitalization due to symptoms, and ICU admittance due to symptoms.

- 158 Participants reporting "No" to a binary question about hospitalization were assigned to a 159 hospital duration of 0 days and designated as negative for ICU admittance due to 160 symptoms.
- 161

162 For association analyses, responses to a question about individual symptoms ("Between the 163 beginning of February 2020 and now, have you had any of the following symptoms?") were 164 converted to a binary variable based on the following mapping: 0 = None, Very Mild, Mild; 1 =165 Moderate, Severe, Very Severe.

166

#### 167 **Association analysis**

168 Analyses were performed either with the statsmodels package in Python3 or in base R with the 169 glm function. For each susceptibility and severity outcome and risk factor of interest, a simple 170 logistic regression (LR) model was fit using unpenalized maximum likelihood (Supplementary 171 Tables 6-14) [23]. Multiple logistic regression was used to adjust the ORs for known COVID-19

exposures and potentially confounding risk factors. The adjusted model included age, sex, and four known exposures (Y/N if any) for susceptibility outcomes; and age, sex, obesity (binarized if BMI >= 30), and health conditions (binarized if any) for severity outcomes (Figures 1 and 2). Individual adjustment variables were omitted when analyzing associations for risk factors within equivalent categories (e.g., age was not included in adjusted models for age bin risk factors).

177

For each risk factor, 95% confidence intervals (CIs) for the log odds ratio were estimated under the normal approximation. The significance threshold was Bonferroni-corrected for the 42 different risk factors examined (adjusted threshold of 0.05/42=0.0012) [23].

181

#### 182 Risk factor selection and risk model training

183 Prior to model training, the data were split with a fixed random seed into training and holdout 184 datasets. We chose risk factors based on a minimal subset of nominally significant ORs within our 185 training data as well as literature guidance [3,4,7,9,11,12,14,15]. For the susceptibility models 186 without symptoms, we included a subset of exposure-related questions, based on the training OR 187 analyses, as well as two demographic variables (age and sex, Supplementary Tables 15-17). For 188 susceptibility models with symptoms, we additionally included the five symptoms most 189 differentiated between symptomatic negative and positive testers from our training ORs. For the 190 severity models, we included pre-existing conditions, based on the training OR analyses, predictive 191 symptoms within our training dataset, morbid obesity (BMI >= 40), age, and sex (Supplementary 192 Table 18).

194	Once final risk factors were selected, we trained LR models with 5-fold cross-validated grid search		
195	on the training dataset to select an optimal lasso regularization parameter lambda [23]. For the grid		
196	search, we scanned 8 different values for lambda, equally partitioned geometrically across a 4-log		
197	space. We then re-trained on the entire training dataset with the optimal lambda and evaluated the		
198	final model on the holdout dataset.		
199			
200	Model thresholding		
201	Phenotypes were predicted from the output of trained models based on a 50% probability threshold		
202	(i.e., logistic model output $> 0.5$ ). Sensitivity and specificity were then calculated based on the true		
203	vs. predicted binary outcomes.		
204			
205	Estimation of performance error		
206	To estimate error in model performances, we bootstrapped our holdout dataset 1,000 times to		
207	generate a sampling distribution for each evaluation metric. We estimated the mean and 95% CIs		
208	for each metric based on the mean and standard deviation of this sampling distribution [23].		
209			

### 211 **RESULTS**

212

#### 213 Survey response and study population

- A total of 563,141 responses were collected, with 4,726 individuals reporting a COVID-19 positive
- test result, 28,872 a negative test result, 71,761 no COVID-19 test but flu-like symptoms, and
- 216 454,542 no COVID-19 and no flu-like symptoms. 3,240 reported pending test results and were
- excluded from further analyses. The survey completion rate was approximately 95%. In general,
- the COVID-19 positive test rate and self-reported clinical outcomes were consistent with those
- 219 reported by the U.S. Centers for Disease Control and Prevention (CDC) over a similar period
- 220 (Supplementary Note 1) [24]. The majority of participants were female (67.5%) and of European
- ancestry (75.4%), with some individuals of Admixed Amerindian (6.5%) or Admixed African-
- European (3.0%) ancestries. The median age of the entire cohort was 56, and the median age of
- those reporting a positive test result was 49 (Table 1 and Supplementary Tables 1-5).

### 225 Table 1. Study population demographic information

	COVID-19 Nasopharyngeal Swab Test Positive	COVID-19 Nasopharyngeal Swab Test Negative	Full AncestryDNA COVID-19 Cohort
	<i>n</i> = 4,726	n = 28,872	n = 563,141
Age			
Median, mean (sd)	49, 49.49 (15.43)	53, 52.68 (15.5)	56, 53.90 (16.13)
Bins (Counts, %)			
18-30	600 (0.13)	2496 (0.09)	52580 (0.09)
31-40	941 (0.2)	5001 (0.17)	87261 (0.15)
41-50	926 (0.2)	5333 (0.18)	90473 (0.16)
51-60	1057 (0.22)	6009 (0.21)	108062 (0.19)
61-70	735 (0.16)	5961 (0.21)	128200 (0.23)
71-90	467 (0.10)	4072 (0.14)	96565 (0.17)
Genetic Sex (counts, %)			
Female	3013 (0.64)	19945 (0.69)	380349 (0.67)
Male	1706 (0.36)	8867 (0.31)	183153 (0.32)
Genetic Ancestry Continental Groupings			
Admixed African-European ancestry	275 (0.06)	1244 (0.04)	17019 (0.03)
Admixed Amerindian ancestry	520 (0.11)	2336 (0.08)	36865 (0.07)
European ancestry	3026 (0.64)	20269 (0.7)	424328 (0.75)
Other ancestry	905 (0.19)	5023 (0.17)	84929 (0.15)
Pre-existing health conditions (any)	1911 (0.46)	15261 (0.55)	255788 (0.47)
BMI (med, mean, sd)	28.59, 29.83 (7.04)	28.67, 29.92 (7.05)	28.29, 29.53 (6.87)
Underweight (count, %)	<100	204	4407
Healthy (count, %)	971	6442	139565
Overweight (count, %)	1225	8503	172941
Obese (count, %)	1629	11264	203325
Flu			
Shot (yes)	2656 (0.63)	19856 (0.71)	356144 (0.65)
Test Dx (yes)	198 (0.05)	1180 (0.04)	11726 (0.02)
Symptoms (tested pos.)			
General, yes (count, % of pos.)	3862 (0.87)		9237 (0.47)
Hospitalization (count, % of positives)	453 (0.11)		1397 (0.02)
Duration, days (med, mean, sd)	5, 7.62 (9.08)		3, 4.78 (7.22)

#### 227 Susceptibility associations: replicated and novel

We replicated many previously reported literature associations for susceptibility. The strongest associations for a positive COVID-19 test result were known COVID-19 exposures, either through a household case (OR=26.03; 95% confidence interval [CI]=(22.26, 30.43)), biological relative (OR=5.77; 95% CI=(4.99, 6.68)), or other source of "direct" exposure (OR=6.94; 95% CI=(6.02, 7.99)) (Figure 1, Supplementary Table 6). In general, adjusting for known exposures, age, and sex resulted in attenuation of the ORs, with many associations becoming insignificant after adjustment

234 (Figure 1, Supplementary Table 7).

235

One novel result was that the OR for males was not attenuated after adjustment, and males remained at elevated odds after adjusting for known exposures and age (aOR=1.36; 95% CI=(1.19, 1.55); Figure 1, Supplementary Table 7). We also note that males and females reported comparable exposure burden, with males slightly more likely to report a household case of COVID-19 but less likely to report a case of COVID-19 among biological relatives (Supplementary Tables 9 and 10).

242

243 Consistent with previous reports [25-29], younger individuals (ages 18-29; OR=1.51; 95% 244 CI=(1.26, 1.81)) were significantly more likely to test positive compared to older individuals (ages 245 50-64, the largest age group in this cohort), and individuals of admixed African-European 246 (OR=1.48; 95% CI=(1.18, 1.85)) or admixed Amerindian ancestry (OR=1.49; 95% CI=(1.26, 247 1.77)) were more likely to test positive compared to those of European ancestry (Supplementary 248 Table 6). Individuals in all three of these groups reported higher levels of COVID-19 cases within 249 the household, cases among biological relatives, and/or other known "direct" COVID-19 250 exposures (Supplementary Tables 8-10). Adjusting for age (ancestry groups only), sex, and known

251	exposures attenuated the OR for all of these groups (younger aOR=1.28; 95% CI=(1.03, 1.59),
252	African-European aOR=1.23; 95% CI=(0.94, 1.62), and Amerindian aOR=1.27; 95% CI=(1.04,
253	1.57); Figure 1, Supplementary Table 7).
254	
255	Individuals reporting pre-existing medical conditions (e.g., cancer, cardiovascular disease, chronic
256	kidney disease [CKD], diabetes, hypertension) were less likely to test positive for COVID-19

257 (Figure 1, Supplementary Table 6). We observed significantly decreased odds of a known "direct"

258 exposure to COVID-19, as well as significantly decreased odds of a household case of COVID-

259 19, among such individuals relative to those without any health conditions (OR=0.71; 95%

260 CI=(0.65, 0.78) and OR=0.74; 95% CI=(0.65, 0.84), respectively; Supplementary Tables 8 and 9).

261

#### 262 Replicated associations for COVID-19 severity

263 Consistent with previous reports [7,9,12,14,15], we observed positive associations between certain 264 health conditions and COVID-19 severity outcomes; many of these associations remained 265 significant after adjustment for age, sex, and obesity (BMI >= 30) (Figure 2, Supplementary Tables 266 11-14). COVID-19 cases reporting at least one underlying health condition were significantly more 267 likely to progress to a critical case (OR=2.85; 95% CI=(1.78, 4.57); Figure 2, Supplementary 268 Figure 1, Supplementary Table 13). Specific underlying health conditions that were associated 269 with hospitalization and/or critical case progression included CKD, chronic obstructive pulmonary 270 disease (COPD), diabetes, cardiovascular disease, and hypertension (Figure 2, Supplementary 271 Figure 1, Tables S12 and S14). Among individuals testing positive for COVID-19, the oldest (≥65 272 years) were significantly more likely to be hospitalized compared to those aged 50-64 (OR=1.70; 273 95% CI=(1.13, 2.56); Figure 2, Supplementary Table 11). Individuals of admixed African-

European ancestry who tested positive were significantly more likely to report progression to a critical case, compared to those with European ancestry (OR=2.07; 95% CI=(1.03, 4.17); Supplementary Figure 1, Supplementary Table 13). Among COVID-19 cases, males were significantly more likely than females to report progression to a critical case (OR=1.54, 95%; CI=(1.00, 2.37); Supplementary Figure 1, Supplementary Table 13); these findings are consistent with CDC reports of increased ICU admittance rates in males (3% vs. 2%) [24].

280

#### 281 Differential symptomology between susceptibility and severity

282 We compared associations between susceptibility and severity to provide a more nuanced view of 283 symptoms associated with a positive test result versus those associated with severe illness 284 progression (Figure 3) [17,18,30]. Among symptomatic people reporting a COVID-19 test result, 285 those reporting change in taste or smell (OR=7.26; 95% CI=(5.54, 9.50)), fever (OR=1.60; 95% 286 CI=(1.28, 2.01)), or feeling tired or fatigue (OR=1.41; 95% CI=(1.05, 1.89)) were more likely to 287 test positive (Figure 3, Supplementary Table 6). Those reporting runny nose (OR=0.59; 95% 288 CI=(0.47, 0.75)) or sore throat (OR=0.49; 95% CI=(0.39, 0.62)) were more likely to test negative, 289 consistent with previous reports that these symptoms are more indicative of influenza or the 290 common cold (Figure 3, Supplementary Table 6) [17,18,30]. Change in taste or smell, a hallmark 291 symptom of COVID-19 infection, was not associated with hospitalization (OR=0.77, 95% 292 CI=(0.55, 1.07); Figure 3, Supplementary Table 11). By contrast, dyspnea (shortness of breath) 293 was strongly associated with hospitalization and critical case progression (OR=7.52; 95% 294 CI=(4.92, 11.49) and OR=11.55; 95% CI=(5.91, 22.59), respectively) [31], but was not associated 295 with a positive test result (OR=1.14; 95% CI=(0.91, 1.44); Figure 3, Supplementary Tables 6, 11, 296 and 13).

#### 298 Predictive risk models

299 We further developed risk models that predict an individual's COVID-19 risk (positive test result 300 or severity, Methods) [7,16–18,32,33]. The susceptibility models were designed to predict a 301 COVID-19 result (positive or negative) from risk factors among testers. We compared four 302 models: our model based on demographics and exposures only ("Dem + Exp"); our model based 303 on demographics, exposures, and symptoms ("Dem + Exp + Symp"); and for benchmarking 304 purposes, a replication of a previously published model called "How We Feel" based on nearly 305 identical self-reported symptoms ("HWF Symp"), and one which also included self-reported 306 exposures ("HWF Exp + Symp") (Supplementary Note 2, Supplementary Table 18) [18].

307

308 All four susceptibility models performed robustly; the three models that included one or more 309 symptoms outperformed the model without symptoms (Dem + Exp), underscoring the value of 310 self-reported symptoms for discriminating between cases and controls (Figure 4, see 311 Supplementary Tables 19-22 for detailed model performance data). The model with demographics, 312 exposures, and symptoms (Dem + Exp + Symp) achieved the highest overall performance with an 313 AUC of  $0.94 \pm 0.02$ , a sensitivity of 85%, and a specificity of 91% (Supplementary Note 3). Each 314 of the models performed comparably across different age, sex, and genetic ancestry cohorts (Figure 315 4, Supplementary Tables 19-22). We observed no significant overfitting in any of the models as 316 evidenced by comparable train-test performances (Supplementary Table 23).

317

We trained two severity models, designed to predict either hospitalization or progression to critical illness among COVID-19 cases. We included a number of risk factors and symptoms most associated with severe COVID-19 outcomes from the literature and/or our training dataset (Figure 3, Supplementary Tables 16 and 17); these included age [7–9,14], sex [4,7,11,12,14], morbid

322	obesity (BMI $\geq$ 40) [7,34], and health conditions [7,9,12,14,15], as well as symptoms including
323	shortness of breath [31], fever, feeling tired or fatigue, dry cough, and diarrhea. Both models
324	performed robustly on an independent holdout dataset (AUCs of 0.87 +/- 0.03 and 0.90 +/- 0.03
325	for the hospitalization and critical models, respectively, Figure 4). The severity models performed
326	comparably when stratifying by age, sex, and genetic ancestry (Figure 4, Supplementary Tables
327	24 and 25), and there was no significant overfitting bias as evidenced by comparable train-test
328	performances (Supplementary Table 23).

329

#### 331 **DISCUSSION**

The AncestryDNA COVID-19 Study provides a highly complete, self-reported dataset that contains information about a plethora of risk factors in the context of COVID-19 susceptibility and severity outcomes. The self-report framework provides fast, low-cost, population-scale data that are particularly valuable in a pandemic, where knowledge is both limited and evolving rapidly based on changing circumstances. Additionally, the broad collection mechanism enables datagathering from many more participants than typically seen in a medical setting, including those with mild or no symptoms, and participants can safely provide data from their homes.

339

340 The study highlights exposure burden as the primary risk factor for COVID-19 susceptibility, and 341 the importance of accounting for known exposures when assessing differences in susceptibility to 342 COVID-19. Few studies have measured and explicitly adjusted for known COVID-19 exposures 343 at this scale [20]. Importantly, we found elevated susceptibility risk in males after adjusting for 344 age and known exposures, and unlike most of the risk factors we evaluated, the adjusted odds were 345 not attenuated compared to the unadjusted odds. This finding is distinct from previous findings on 346 elevated severity risk in males [4,7,11]. This result could be due to differences between men and 347 women in behaviors, unknown exposures, biology, genetics [4–6], or other risk factors not 348 measured within this dataset and should be investigated in future studies.

349

Another major contribution of this study is the use of self-reported data for the development of novel risk models for predicting an individual's COVID-19 susceptibility and severity risk. The risk models presented here perform comparably or better than similar and more complex models reported previously [16–18,32,33]. Although some previously reported risk models have been

assessed in different age or sex cohorts [16,17], we are not aware of any that have been assessed across genetic ancestry cohorts [7,16–18,32,33], highlighting the potential utility and generalizability of the models to broader populations [17,18,30].

357

#### 358 Limitations

359 We note that there are some inherent limitations of self-reported data for studying COVID-19 risk 360 factors. The most severe cases, especially those resulting in mortality, were not sampled. As a 361 result, many of the risk factor effect estimates may be underestimated. Additionally, the 362 AncestryDNA cohort is self-selected, slightly older, more European, and more female than the 363 broader U.S. population. Another potential issue is that those who reported a negative test may 364 have underestimated their exposures and symptoms relative to those who tested positive, leading 365 to upwardly biased exposure effect estimates. Finally, misclassification of COVID-19 positive 366 status is likely given the uneven availability of tests over the time period surveyed, potentially 367 leading to susceptibility effect estimates that are biased toward the null. However, the fact that 368 most of the associations observed in this study were similar to those previously reported in the 369 literature and the fact that risk model performance remained high when data were stratified by age, 370 sex, and genetic ancestry lends confidence to our findings in spite of limitations.

371

372

# 374 CONCLUSION

- 375 The COVID-19 pandemic has exacted a historic toll on healthcare systems and global economies
- 376 and continues to evolve based on changes in human behavior, public health guidelines, and societal
- 377 factors. This study demonstrates the power of a self-reported data in a large cohort to rapidly
- 378 elucidate more details about COVID-19 risk factors and help point the way to minimizing disease
- burden.
- 380
- 381

#### 382 Acknowledgements

We thank our AncestryDNA customers who made this study possible by contributing information about their experience with COVID-19 through our survey. Without them, this work would not be possible. We would like to thank Zach Bass, Robert Dowling, Disha Akarte, Swapnil Sneham, Sean Enright and the entire Cyborg team for their tireless work in the release and continued support of the COVID-19 survey.

388

#### 389 **Contributors**

390 SCK, SRM, BR contributed equally to the manuscript and wrote the first draft of the paper. ARG 391 provided direct project guidance and lead the COVID-19 research teams. SCK, SRM, BR 392 performed the association analyses. SCK developed and assessed the risk models. MVC and KAR 393 designed the COVID-19 survey questionnaire. SCK and DP supported the dataset creation. GHLR 394 supported the phenotype definitions. MVC and NDB built the demographic tables. SCK, SRM, 395 BR, MVC, GHLR, ARG, and KAR helped with additional analyses and interpretation. MZ, DP, 396 DT, KD, MP, HG, AKHB helped with the EGA dataset. The AncestryDNA Science Team 397 contributed to additional work, allowing for the completion of the COVID-19 research and 398 manuscript. KAR, ELH, and CAB provided additional project guidance. All authors contributed 399 to the final manuscript.

400

#### 401 AncestryDNA Science Team

402 Yambazi Banda, Ke Bi, Robert Burton, Marjan Champine, Ross Curtis, Abby Drokhlyansky,
403 Ashley Elrick, Cat Foo, Michael Gaddis, Jialiang Gu, Shannon Hateley, Heather Harris, Shea
404 King, Christine Maldonado, Evan McCartney-Melstad, Alexandra McFarland, Patty Miller, Luong

405	Nguyen, Keith Noto, Jingwen Pei, Jenna Petersen, Scott Pew, Chodon Sass, Josh Schraiber, Alisa		
406	Sedghifar, Andrey Smelter, Sarah South, Barry Starr, Cecily Vaughn, Yong Wang		
407			
408	Funding		
409	All work was supported and funded by Ancestry.com, a privately owned corporation.		
410			
411	Competing interests		
412	Authors affiliated with AncestryDNA may have equity in Ancestry.		
413			
414	Patient consent for publication		
415	Not required.		
416			
417	Data availability statement		
418	A dataset (EGAC00001001762) is available to qualified scientists through the European Genome-		
419	phenome Archive (EGA). The EGA dataset includes the risk factors and outcomes studied here.		
420	The EGA dataset is de-identified and comprises ~15,000 individuals who tested for COVID-19,		
421	including more than 3,000 individuals who tested positive, many of whom are in this study. The		
422	EGA cohort is sufficient to nominally replicate the vast majority of susceptibility and severity		
423	associations from this study. Risk models trained within the EGA cohort achieve comparable		
424	discriminative performance to the models presented here when evaluated in an independent		
425	holdout dataset (Supplementary Figure 5).		

## 427 **REFERENCES**

- World Health Organization. Coronavirus Disease (COVID-19)– Weekly Epidemiological
  Update. 2021.https://www.who.int/publications/m/item/weekly-epidemiological-update---5january-2021 (accessed 6 Jan 2021).
- 431 2 U.S. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019
- 432 (COVID-19): CDC COVID Data Tracker. 2021.https://covid.cdc.gov/covid-data 433 tracker/#cases\_casesper100klast7days (accessed 6 Jan 2021).
- 434 3 CMMID COVID-19 working group, Davies NG, Klepac P, *et al.* Age-dependent effects in
  435 the transmission and control of COVID-19 epidemics. *Nat Med* 2020;**26**:1205–11.
  436 doi:10.1038/s41591-020-0962-9
- 437 4 Yale IMPACT research team, Takahashi T, Ellingson MK, *et al.* Sex differences in immune
  438 responses that underlie COVID-19 disease outcomes. *Nature* Published Online First: 26
  439 August 2020. doi:10.1038/s41586-020-2700-3
- Koberts GHL, Park DS, Coignet MV, *et al.* AncestryDNA COVID-19 Host Genetic Study
  Identifies Three Novel Loci. Epidemiology 2020. doi:10.1101/2020.10.06.20205864
- 442 6 Zhao Y, Zhao Z, Wang Y, *et al.* Single-cell RNA expression profiling of ACE2, the receptor
  443 of SARS-CoV-2. *medRXiv* Published Online First: 26 January 2020.
  444 doi:10.1101/2020.01.26.919985
- Williamson EJ, Walker AJ, Bhaskaran K, *et al.* Factors associated with COVID-19-related
  death using OpenSAFELY. *Nature* 2020;**584**:430–6. doi:10.1038/s41586-020-2521-4
- Liu Y, Mao B, Liang S, *et al.* Association between age and clinical characteristics and
  outcomes of COVID-19. *Eur Respir J* 2020;55:2001112. doi:10.1183/13993003.01112-2020
- 449 9 Li X, Xu S, Yu M, *et al.* Risk factors for severity and mortality in adult COVID-19 inpatients
  450 in Wuhan. *J Allergy Clin Immunol* 2020;**146**:110–8. doi:10.1016/j.jaci.2020.04.006
- Clark A, Jit M, Warren-Gash C, *et al.* Global, regional, and national estimates of the
  population at increased risk of severe COVID-19 due to underlying health conditions in
  2020: a modelling study. *Lancet Glob Health* 2020;8:e1003–17. doi:10.1016/S2214109X(20)30264-3
- 455 11 Gebhard C, Regitz-Zagrosek V, Neuhauser HK, *et al.* Impact of sex and gender on COVID456 19 outcomes in Europe. *Biol Sex Differ* 2020;11:29. doi:10.1186/s13293-020-00304-9
- 457 12 Grasselli G, Zangrillo A, Zanella A, *et al.* Baseline Characteristics and Outcomes of 1591
   458 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.
   459 JAMA 2020;323:1574. doi:10.1001/jama.2020.5394

- 460 13 Ellinghaus D, Degenhardt F, Bujanda L, *et al.* Genomewide Association Study of Severe
  461 Covid-19 with Respiratory Failure. *N Engl J Med* 2020;:NEJMoa2020283.
  462 doi:10.1056/NEJMoa2020283
- 463 14 Richardson S, Hirsch JS, Narasimhan M, *et al.* Presenting Characteristics, Comorbidities,
  464 and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City
  465 Area. *JAMA* 2020;**323**:2052. doi:10.1001/jama.2020.6775
- 466 15 Guan W, Liang W, Zhao Y, *et al.* Comorbidity and its impact on 1590 patients with COVID467 19 in China: a nationwide analysis. *Eur Respir J* 2020;55:2000547.
  468 doi:10.1183/13993003.00547-2020
- 469 16 Wynants L, Van Calster B, Collins GS, *et al.* Prediction models for diagnosis and prognosis
  470 of covid-19: systematic review and critical appraisal. *BMJ* 2020;:m1328.
  471 doi:10.1136/bmj.m1328
- 472 17 Menni C, Valdes AM, Freidin MB, *et al.* Real-time tracking of self-reported symptoms to
  473 predict potential COVID-19. *Nat Med* 2020;**26**:1037–40. doi:10.1038/s41591-020-0916-2
- Allen WE, Altae-Tran H, Briggs J, *et al.* Population-scale longitudinal mapping of COVID19 symptoms, behaviour and testing. *Nat Hum Behav* 2020;4:972–82. doi:10.1038/s41562020-00944-2
- 477 19 Martin LM, Leff M, Garrett C, *et al.* Validation of self-reported chronic conditions and
  478 health services in a managed care population. *Am J Prev Med* 2000;18:215–8.
  479 doi:10.1016/s0749-3797(99)00158-0
- 480 20 Nguyen LH, Drew DA, Graham MS, *et al.* Risk of COVID-19 among front-line health-care
  481 workers and the general community: a prospective cohort study. *Lancet Public Health*482 2020;5:e475-83. doi:10.1016/S2468-2667(20)30164-X
- 483 21 Han E, Carbonetto P, Curtis RE, *et al.* Clustering of 770,000 genomes reveals post-colonial
  484 population structure of North America. *Nat Commun* 2017;**8**:14238.
  485 doi:10.1038/ncomms14238
- 486 22 Ball CA. Ethnicity Estimate 2019 White Paper.
  487 2019.https://www.ancestrycdn.com/dna/static/pdf/whitepapers/EV2019\_white\_paper\_2.pdf
  488 (accessed 1 Aug 2020).
- 489 23 Hastie T. *The Elements of Statistical Learning: Data Mining, Inference, and Prediction.* 2nd
  490 ed. New York: : Springer 2009.
- 491 24 Stokes EK, Zambrano LD, Anderson KN, *et al.* Coronavirus Disease 2019 Case Surveillance
  492 United States, January 22–May 30, 2020. *MMWR Morb Mortal Wkly Rep* 2020;**69**:759–
- 493 65. doi:10.15585/mmwr.mm6924e2

	195 196	20	Vulnerabilities: Implications for Health Equity, New Haven, Connecticut. <i>AIDS Behav</i> 2020; <b>24</b> :2007–8. doi:10.1007/s10461-020-02921-2
4	197 198 199	26	Price-Haywood EG, Burton J, Fort D, <i>et al.</i> Hospitalization and Mortality among Black Patients and White Patients with Covid-19. <i>N Engl J Med</i> 2020; <b>382</b> :2534–43. doi:10.1056/NEJMsa2011686
	500 501	27	Millett GA, Jones AT, Benkeser D, et al. Assessing differential impacts of COVID-19 on black communities. <i>Ann Epidemiol</i> 2020; <b>47</b> :37–44. doi:10.1016/j.annepidem.2020.05.003
	502 503	28	Webb Hooper M, Nápoles AM, Pérez-Stable EJ. COVID-19 and Racial/Ethnic Disparities. <i>JAMA</i> 2020; <b>323</b> :2466. doi:10.1001/jama.2020.8598
4	504 505 506	29	Julie Bosman, Mervosch S. As virus surges, younger people account for 'disturbing' number of cases. N. Y. Times. 2020.https://www.nytimes.com/2020/06/25/us/coronavirus-cases-young-people.html
4	507 508 509	30	Chow EJ, Schwartz NG, Tobolowsky FA, <i>et al.</i> Symptom Screening at Illness Onset of Health Care Personnel With SARS-CoV-2 Infection in King County, Washington. <i>JAMA</i> 2020; <b>323</b> :2087. doi:10.1001/jama.2020.6637
4	510 511	31	Shi L, Wang Y, Wang Y, <i>et al.</i> Dyspnea rather than fever is a risk factor for predicting mortality in patients with COVID-19. <i>J Infect</i> 2020;:S0163445320302887.

25 Rosenberg A, Keene DE, Schlesinger P, et al. COVID-19 and Hidden Housing

512 doi:10.1016/j.jinf.2020.05.013

- 513 32 Jehi L, Ji X, Milinovich A, *et al.* Individualizing Risk Prediction for Positive Coronavirus
  514 Disease 2019 Testing. *Chest* 2020;:S0012369220316548. doi:10.1016/j.chest.2020.05.580
- 33 Jehi L, Ji X, Milinovich A, *et al.* Development and validation of a model for individualized
  prediction of hospitalization risk in 4,536 patients with COVID-19. *PLOS ONE*2020;15:e0237419. doi:10.1371/journal.pone.0237419
- 518 34 Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. *Obesity* 519 2020;28:1005–1005. doi:10.1002/oby.22818

520

### 521 FIGURES






Figure 1. Susceptibility odds ratios (ORs) and 95% confidence intervals (CIs) estimated from
 simple ("Unadjusted models," grey) and multiple ("Adjusted models," black) logistic
 regression with adjustment for other risk factors. Open circles indicate not significant (p-value)

526	> 0.05) after accounting for multiple hypothesis tests using Bonferroni correction. Age, sex,
527	genetic ancestry, and obesity ORs were estimated in relation to the reference variables indicated.
528	Exposure, health, and symptom ORs were each estimated separately as binary variables. Symptom
529	ORs were estimated as binary variables among symptomatic testers only (Methods). Risk factor
530	adjustments for susceptibility include: sex, age, and at least one known COVID-19 exposure.
531	Where applicable, individual adjustment variables were omitted to avoid duplicate adjustment
532	(Methods).

533




Figure 2. Severity (hospitalization) odds ratios (ORs) and 95% confidence intervals (CIs)
estimated from simple ("Unadjusted models," grey) and multiple ("Adjusted models," black)
logistic regression with adjustment for other risk factors. Open circles indicate not significant

539	(p-value > 0.05) after accounting for multiple hypothesis tests using Bonferroni correction. Age,
540	sex, genetic ancestry, and obesity ORs were estimated in relation to the reference variables
541	indicated. Exposure, health, and symptom ORs were each estimated separately as binary variables.
542	Symptom ORs were estimated as binary variables among symptomatic testers only (Methods).
543	Risk factor adjustments for severity include: sex, age, obesity (Y/N), and underlying health
544	conditions (Y/N if any). Where applicable, individual adjustment variables were omitted to avoid
545	duplicate adjustment (Methods). See Supplementary Figure 1 for critical case severity ORs.
<b>5</b> A C	





Figure 3. Comparison of susceptibility adjusted ORs (horizontal axis) and severity adjusted ORs (vertical axis) for symptoms in Figures 1 and 2. Severity aORs are for hospitalization. Note that aORs for susceptibility and severity are adjusted differently according to descriptions in Figure 1 and 2 captions. Adjusted ORs are plotted on a log scale for visibility. Shortness of breath is the strongest indicator of increased severity, while change in taste or smell is the strongest indicator for testing positive for COVID-19 among symptomatic individuals (Methods). Refer to Supplementary Figure 2 for demographic, health condition, and exposure aORs.

555

547



557

558 Figure 4. Performance of risk models on independent holdout data. A) Receiver operating 559 characteristic (ROC) curves for susceptibility models to predict COVID-19 cases among testers 560 reporting a result (positive or negative). B) Area under the curve (AUC) for the four susceptibility 561 models in A), stratified by cohort. "All" represents everyone in A). C) ROC curves for severity 562 models to predict either hospitalization (red) or critical illness progression (black) among COVID-563 19 cases. D) Area under the curve (AUC) for the two severity models in B), stratified by cohort. 564 "All" represents everyone in C). Refer to Methods as well as Supplementary Figure 3 and 565 Supplementary Tables 18-25 for additional model performance data and model risk factor 566 information.

# **1 SUPPORTING INFORMATION**

# 2 COVID-19 susceptibility and severity risks in a survey

# 3 of over 500,000 individuals

Spencer C. Knight\*<sup>1</sup>, Shannon R. McCurdy\*<sup>1</sup>, Brooke Rhead\*<sup>1</sup>, Marie V. Coignet<sup>1</sup>, Danny S.
Park<sup>1</sup>, Genevieve H.L. Roberts<sup>2</sup>, Nathan D. Berkowitz<sup>1</sup>, Miao Zhang<sup>1</sup>, David Turissini<sup>1</sup>, Karen Delgado<sup>2</sup>, Milos Pavlovic<sup>2</sup>, AncestryDNA Science Team<sup>2</sup>, Asher K. Haug Baltzell<sup>2</sup>, Harendra Guturu<sup>1</sup>, Kristin A. Rand<sup>1</sup>, Ahna R. Girshick<sup>1</sup>, Eurie L. Hong<sup>1</sup>, Catherine A. Ball<sup>1</sup>

- 9 \*These authors contributed equally to this work.
- 10 1. AncestryDNA, 153 Townsend St, Suite 800, San Francisco, CA, 94107
- 11 2. AncestryDNA, 1300 West Traverse Parkway, Lehi, UT 84043
- 12
- 13 Corresponding Author: Kristin A. Rand, AncestryDNA, 153 Townsend St, Suite 800, San
- 14 Francisco, CA 94107, United States of America (e-mail: kristinmuench@gmail.com)
- 15
- 16 Keywords: COVID-19, Modeling, Genetic Epidemiology, Statistics
- 17
- 18 Abbreviations: aOR (adjusted odds ratio), AUC (area under the curve), BMI (body mass index),
- 19 CI (confidence interval), CDC (U.S. Centers for Disease Control), CKD (chronic kidney disease),
- 20 COPD (chronic obstructive pulmonary disease), EGA (European Genome-phenome Archive),
- 21 GWAS (genome-wide association studies), HWF ("How We Feel" study), ICU (intensive care
- 22 unit), LR (logistic regression), OR (odds ratio), ROC (receiver operating characteristic)

- 24
- 25

#### 26 SUPPLEMENTARY NOTES

27

28 Supplementary Note 1. Comparison of AncestryDNA data to CDC data. In general, the 29 COVID-19 testing results are consistent with those reported by the U.S. Centers for Disease 30 Control and Prevention (CDC) over a similar period [24]. For example, the CDC reported a 12% 31 cumulative overall positive test rate from 1 March to 30 May 2020, while 14.1% of AncestryDNA 32 survey participants reported testing positive (the denominator includes tests with "results 33 pending"). For hospitalization, the CDC reported that 14% of individuals testing positive for 34 COVID-19 were hospitalized, and 2% were admitted to an intensive care unit (ICU), between 22 35 January and 30 May 2020. Among the AncestryDNA survey respondents, 11% of those reporting 36 a positive COVID-19 test were hospitalized, and 4.9% were admitted to ICU between April 22 37 and July 6, 2020.

38

39 Supplementary Note 2. Risk factors for predictive susceptibility models. The HWF Exp + 40 Symp model includes three risk factors, including two exposures and one symptom (change in 41 taste or smell, Supplementary Table 18). The HWF Symp model includes seven symptoms most 42 commonly associated with COVID-19 according to the CDC (Supplementary Table 18) [18]. For 43 the Dem + Exp and Dem + Exp + Symp models, we incorporated responses to several exposure 44 questions that were primary risk factors in the OR analysis of the training set (Methods and 45 Supplementary Table 15) [18]. We also considered age and sex, given their nominal association 46 with COVID-19 in our ORs in the training dataset, as well as reports about these variables as risk 47 factors (Supplementary Table 15) [3,4,29]. For Dem + Exp + Symp model, we selected the most 48 differentiated symptoms between cases and controls amongst symptomatic COVID-19 testers

within the training dataset, including fever, change in taste or smell, feeling tired/fatigued, runny
nose, and sore throat [17,18,30].

51

### 52 Supplementary Note 3. Comparison of AncestryDNA and HWF cohorts and performances. 53 The HWF models performed better when trained and evaluated on the AncestryDNA dataset as 54 compared with the HWF dataset, particularly for the symptoms-only model (HWF Symp: 55 AncestryDNA-trained AUC=0.87 and HWF-trained AUC=0.76 and HWF Exp + Symp: 56 AncestryDNA-trained AUC=0.90 and HWF-trained AUC=0.87; Figure 4) [18]. This result could 57 be due to differences in survey flow design, demographics, or the relative prevalences of self-58 reported symptoms between the two datasets. We re-trained and evaluated our models on a subset 59 of symptomatic COVID-19 testers (positives and negatives) reporting at least one symptom of 60 moderate or greater intensity. The performances of all models that included symptoms were 61 slightly attenuated in this cohort, with AUCs for the HWF models approaching previous reports 62 (HWF Symp: AncestryDNA-trained AUC=0.80 and HWF Exp + Symp: AncestryDNA-trained 63 AUC=0.87); the model without symptoms performed the same (Supplementary Figure 4). This 64 suggests that predicting COVID-19 cases on the basis of symptoms alone is more challenging 65 when symptoms are less differentiated between positive and negative testers.

# 67 SUPPLEMENTARY TABLES

### 68 Supplementary Table 1. Selected subset of survey questions considered in the context of

- 69 COVID-19 severity outcomes analysis and modeling efforts.
- 70

Risk factor description	Question	Possible responses
COVID-19 test result	Have you been swab tested for COVID-19, commonly referred to as coronavirus?	Yes, and was positive; Yes, and was negative; Yes, and my results are pending; No, but I have had flu-like symptoms with a fever at some point since the beginning of February 2020; No, and I have not had flu-like symptoms at some point since the beginning of February 2020
Case amongst direct biological relatives (multi- choice)	Have any of your biological relatives tested positive for COVID-19? Select all that apply.	Grandparent(s); Parent(s); Child(ren); Sibling(s); Other; None
Healthcare worker routinely exposed to COVID-19	Are you a healthcare professional working directly with or in close physical proximity to patients who have tested positive for COVID-19?	Yes; No; Not sure
Household case of COVID-19	Has someone in your household tested positive for COVID- 19?	Yes; No; Not sure
Number of household cases of COVID-19	How many people in your household have tested positive for COVID-19?	Numeric
Known direct COVID-19 exposure	Have you been directly exposed to someone who has tested positive for COVID-19?	Yes; No; Not sure
Health condition(s)	Do you currently have any of the following health conditions? Select all that apply.	Asthma,COPD (Chronic Obstructive Pulmonary Disease); Other lung condition; Cancer (treated in the past year); Cardiovascular disease; Chronic kidney disease; Diabetes; Hypertension; Organ failure requiring a transplant (in the last year); Blood disorder requiring hematopoietic stem cell / bone marrow transplant; Other autoimmune disease; Other immunodeficiency disorder; Other; None; Not sure

71

72 The survey flow was as described previously [5], with the addition of symptom and clincial

73 assessment for negative testers.

## 74 Supplementary Table 2. Selected risk factors considered in susceptibility or severity

#### 75 outcomes analysis and modeling efforts.

Risk factor		
description	Question	Possible responses
COVID-19 test result	Have you been swab tested for COVID-19, commonly referred to as coronavirus?	Yes, and was positive; Yes, and was negative; Yes, and my results are pending; No, but I have had flu-like symptoms with a fever at some point since the beginning of February 2020; No, and I have not had flu-like symptoms at some point since the beginning of February 2020
Symptoms (binary)	Did you experience symptoms as a result of your condition?	Yes; No; Not sure
Symptoms (multi- choice)	Between the beginning of February 2020 and now, have you had any of the following symptoms?	Fever; Shortness of breath; Dry cough; Nasal congestion; Runny nose; Sore throat; Feeling tired or fatigue; Chills; Body aches; Headache; Cough producing phlegm; Abdominal pain; Nausea or vomiting; Diarrhea; Change in taste or smell
Symptom duration (multi- choice)	How long did these symptoms last?	Less than 1 day; 1-3 days; 4-7 days; 8-14 days; 2 weeks to a month; 1-3 months; More than 3 months
Hospitalization	Were you hospitalized due to these symptoms?	Yes; No; Not sure
Hospital duration	How long were you hospitalized?	Numeric
ICU with ventilator	Were you hospitalized in the Intensive Care Unit (ICU) with a ventilator?	Yes; No; Not sure
ICU with oxygen	Were you hospitalized in the Intensive Care Unit (ICU) with oxygen?	Yes; No; Not sure
Illness complications (multi-choice)	Have you had any of the following complications due to your illness? Select all that apply.	None; Pneumonia; Severe pneumonia leading to hospitalization; Respiratory failure; Septic shock; Multiple organ dysfunction or failure; Blood clots; Stroke; Other

The survey flow was as described previously [5], with the addition of symptom and clincialassessment for negative testers.

## 85 Supplementary Table 3. Demographics for susceptibility modeling cohort

86

	COVID-19 Nasopharyngeal Swab Test Positive	COVID-19 Nasopharyngeal Swab Test Negative	Total Susceptibility modeling cohort (symptom data not required)
	<i>n</i> = 2,505	<i>n</i> = 16,830	<i>n</i> = 19,335
Age			
Median, mean (sd)	48, 47.96 (14.68)	53, 52.93 (15.5)	53, 52.29 (15.49)
Bins (Counts, %)			
18-30	350 (0.14)	1404 (0.08)	1754 (0.09)
31-40	531 (0.21)	2882 (0.17)	3413 (0.18)
41-50	511 (0.2)	3073 (0.18)	3584 (0.19)
51-60	580 (0.23)	3478 (0.21)	4058 (0.21)
61-70	365 (0.15)	3548 (0.21)	3913 (0.20)
71-90	168 (0.07)	2445 (0.15)	2613 (0.14)
Genetic Sex (counts, %)			
Female	1646 (0.66)	11688 (0.69)	13334 (0.69)
Male	859 (0.34)	5142 (0.31)	6001 (0.31)
Genetic Ancestry Continental Groupings			
Admixed African-European ancestry	130 (0.05)	730 (0.04)	860 (0.04)
Admixed Amerindian ancestry	287 (0.11)	1319 (0.08)	1606 (0.08)
European ancestry	1633 (0.65)	11886 (0.71)	13519 (0.70)
Other ancestry	455 (0.18)	2885 (0.17)	3350 (0.17)
Pre-existing health conditions (any)	1131 (0.45)	9168 (0.54)	10299 (0.53)
BMI (med, mean, sd)			
Total	28.7, 29.95 (7.16)	28.52, 29.88 (6.99)	28.73, 30.02 (7.08
Underweight (count, %)	<100	111	135
Healthy (count, %)	629	4051	4680
Overweight (count, %)	759	5433	6192
Obese (count, %)	1069	7012	8081
Flu			
Shot (yes)	1617 (0.65)	12029 (0.71)	13646 (0.71)
Test Dx (yes)	125 (0.05)	761 (0.05)	886 (0.05)
Symptoms (tested pos.)			
General, yes (count, % of pos.)	2254 (0.9)	-	2905 (0.45)
Hospitalization (count, % of positives)	260 (0.11)	-	292 (0.09)
Duration, days (med, mean, sd)	5, 6.68 (8.46)	-	4.5, 6.42 (8.08)

## 89 Supplementary Table 4. Demographics for severity modeling cohort

90

	COVID-19 Nasopharyngeal Swab Test Positive
	n = 3,585
Age	
Median, mean (sd)	49, 48.62 (14.68)
Bins (Counts, %)	
18-30	463 (0.13)
31-40	725 (0.2)
41-50	748 (0.21)
51-60	832 (0.23)
61-70	555 (0.15)
71-90	262 (0.07)
Genetic Sex (counts, %)	
Female	2303 (0.64)
Male	1282 (0.36)
Genetic Ancestry Continental Groupings	
Admixed African-European ancestry	203 (0.06)
Admixed Amerindian ancestry	397 (0.11)
European ancestry	2317 (0.65)
Other ancestry	668 (0.19)
Pre-existing health conditions (any)	1666 (0.46)
BMI (med, mean, sd)	28.67, 29.83 (7.03)
Underweight (count, %)	<100
Healthy (count, %)	884
Overweight (count, %)	1128
Obese (count, %)	1498
Flu	
Shot (yes)	2293 (0.64)
Test Dx (yes)	174 (0.05)
Symptoms (tested pos.)	
General, yes (count, % of pos.)	3236 (0.9)
Hospitalization (count, % of positives)	391 (0.11)
Duration, days (med, mean, sd)	5, 7.34 (8.73)

93	Supplementary	Table 5. Demog	raphics for susc	eptibility mod	els with symptoms

	Susceptibility modeling cohort (with symptom data)
	<i>n</i> = 4,094
Age	
Median, mean (sd)	58, 55.7 (15.82)
Bins (Counts, %)	
18-30	293 (0.07)
31-40	567 (0.14)
41-50	641 (0.16)
51-60	795 (0.19)
61-70	982 (0.24)
71-90	816 (0.20)
Genetic Sex (counts, %)	
Female	2744 (0.67)
Male	1350 (0.33)
Genetic Ancestry Continental Groupings	
Admixed African-European ancestry	172 (0.04)
Admixed Amerindian ancestry	298 (0.07)
European ancestry	2927 (0.72)
Other ancestry	666 (0.16)
Pre-existing health conditions (any)	2205 (0.54)
BMI (med, mean, sd)	28.59, 29.8 (6.84)
Underweight (count, %)	<100
Healthy (count, %)	1007
Overweight (count, %)	1335
Obese (count, %)	1662
Flu	
Shot (yes)	2935 (0.72)
Test Dx (yes)	160 (0.04)
Symptoms (tested pos.)	
General, yes (count, % of pos.)	1037 (0.25)
Hospitalization (count, % of positives)	<100
Duration, days (med, mean, sd)	5, 7.53 (10.11)

## 96 Supplementary Table 6. Unadjusted risk factor odds ratios for COVID-19 susceptibility

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.51	(1.26, 1.81)	0.4108	0.0563	3.05E-13	1.28E-11
Ages 30-49	1.10	(0.97, 1.24)	0.0944	0.0377	1.22E-02	5.14E-01
Ages 50-64	1.00		0		nan	nan
Ages 65+	0.68	(0.59, 0.79)	-0.3819	0.0454	0.00E+00	0.00E+00
GENETIC ANCESTRY						
Admixed African-European	1.48	(1.18, 1.85)	0.3925	0.0694	1.57E-08	6.58E-07
European	1.00		0		nan	nan
Admixed Amerindian	1.49	(1.26, 1.77)	0.3995	0.0523	2.10E-14	8.82E-13
Other	1.21	(1.06, 1.38)	0.188	0.041	4.62E-06	1.94E-04
EXPOSURE						
Any	8.72	(7.42, 10.26)	2.1659	0.0501	0.00E+00	0.00E+00
Biological relative tested positive	5.77	(4.99, 6.68)	1.7529	0.045	0.00E+00	0.00E+00
Directly exposed to someone who tested positive	6.94	(6.02, 7.99)	1.9366	0.0438	0.00E+00	0.00E+00
Healthcare worker directly exposed	1.44	(1.26, 1.65)	0.367	0.0408	2.31E-19	9.69E-18
Household member tested positive	26.03	(22.26, 30.43)	3.2591	0.0482	0.00E+00	0.00E+00
HEALTH CONDITIONS						
Asthma	0.81	(0.71, 0.94)	-0.2046	0.0446	4.55E-06	1.91E-04
COPD (Chronic Obstructive Pulmonary Disease)	0.58	(0.41, 0.82)	-0.5374	0.1057	3.72E-07	1.56E-05
Cancer treated in the past year	0.53	(0.36, 0.80)	-0.6283	0.1237	3.80E-07	1.59E-05
Cardiovascular disease	0.71	(0.56, 0.91)	-0.3383	0.0762	9.12E-06	3.83E-04
Chronic kidney disease	0.54	(0.33, 0.87)	-0.6241	0.148	2.48E-05	1.04E-03
Diabetes	0.86	(0.71, 1.03)	-0.1547	0.0561	5.79E-03	2.43E-01
Hypertension	0.78	(0.68, 0.89)	-0.2522	0.0411	8.08E-10	3.40E-08
Other	0.91	(0.73, 1.13)	-0.0939	0.0675	1.64E-01	1.00E+00
Other autoimmune disease	0.77	(0.65, 0.92)	-0.2571	0.054	1.95E-06	8.20E-05
Other immunodeficiency disorder	0.77	(0.53, 1.14)	-0.2552	0.1194	3.25E-02	1.00E+00
Other lung condition	0.59	(0.42, 0.82)	-0.5355	0.1037	2.45E-07	1.03E-05

Any	0.69	(0.62, 0.77)	-0.3667	0.0336	0.00E+00	0.00E+00
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	0.99	(0.86, 1.13)	-0.0146	0.043	7.35E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.00	(0.83, 1.19)	-0.0042	0.056	9.41E-01	1.00E+00
obesity III (BMI >= 40)	0.97	(0.80, 1.19)	-0.0255	0.0622	6.81E-01	1.00E+00
Not obese	1.00		0		nan	nan
GENETIC SEX						
Female	1.00		0		nan	nan
Male	1.27	(1.14, 1.42)	0.2419	0.0329	1.89E-13	7.95E-12
SYMPTOMS						
Abdominal pain	1.01	(0.77, 1.33)	0.0139	0.0841	8.69E-01	1.00E+00
Body aches	1.34	(1.06, 1.69)	0.2945	0.0717	4.04E-05	1.70E-03
Change in taste or smell	7.26	(5.54, 9.50)	1.9819	0.0832	1.62E-125	6.81E-124
Chills	1.37	(1.09, 1.71)	0.3126	0.0697	7.23E-06	3.04E-04
Cough producing phlegm	0.88	(0.69, 1.12)	-0.1318	0.0746	7.74E-02	1.00E+00
Diarrhea	1.22	(0.96, 1.56)	0.2006	0.0745	7.11E-03	2.99E-01
Dry cough	1.12	(0.89, 1.40)	0.109	0.0694	1.16E-01	1.00E+00
Feeling tired or fatigue	1.41	(1.05, 1.89)	0.343	0.0901	1.41E-04	5.91E-03
Fever	1.60	(1.28, 2.01)	0.4715	0.0701	1.74E-11	7.30E-10
Headache	1.12	(0.88, 1.41)	0.1098	0.0728	1.32E-01	1.00E+00
Nasal congestion	0.74	(0.59, 0.92)	-0.3072	0.0696	1.01E-05	4.24E-04
Nausea or vomiting	0.99	(0.75, 1.32)	-0.0055	0.0867	9.50E-01	1.00E+00
Runny nose	0.59	(0.47, 0.75)	-0.5245	0.0725	4.49E-13	1.89E-11
Shortness of breath	1.14	(0.91, 1.44)	0.1343	0.0705	5.67E-02	1.00E+00
Sore throat	0.49	(0.39, 0.62)	-0.7052	0.0717	8.10E-23	0.00E+00

98

99 Unadjusted odds ratios for a positive COVID-19 test were calculated among survey participants 100 reporting a test result (positive or negative) based on the self-reported response to the following 101 question: "Have you been swab tested for COVID-19, commonly referred to as coronavirus?" The 102 following groups served as reference populations for the odds ratio calculations: European genetic 103 ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, 104 Obesity). Note that symptoms odds ratios were calculated in a binary fashion among symptomatic 105 customers only (Methods).

## 107 Supplementary Table 7. Risk factor odds ratios for COVID-19 susceptibility, adjusted for

### 108 exposure, age, and sex

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.28	(1.03, 1.59)	0.2448	0.0672	2.72E-04	1.14E-02
Ages 30-49	0.94	(0.81, 1.09)	-0.0583	0.0453	1.97E-01	1.00E+00
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	0.96	(0.79, 1.18)	-0.0372	0.0613	5.44E-01	1.00E+00
GENETIC ANCESTRY						
Admixed African-European	1.23	(0.94, 1.62)	0.2091	0.0852	1.42E-02	5.95E-01
European	1.00		0.0000		nan	nan
Admixed Amerindian	1.27	(1.04, 1.57)	0.2417	0.0636	1.46E-04	6.11E-03
Other	1.09	(0.92, 1.29)	0.0863	0.0509	8.98E-02	1.00E+00
EXPOSURE						
Any	8.63	(7.31, 10.19)	2.1555	0.0512	0.00E+00	0.00E+00
Biological relative tested positive	5.68	(4.90, 6.58)	1.7372	0.0455	0.00E+00	0.00E+00
Directly exposed to someone who tested positive	6.71	(5.80, 7.76)	1.9034	0.0451	0.00E+00	0.00E+00
Healthcare worker directly exposed	1.33	(1.16, 1.52)	0.2823	0.0420	1.75E-11	7.34E-10
Household member tested positive	25.09	(21.44, 29.36)	3.2224	0.0485	0.00E+00	0.00E+00
HEALTH CONDITIONS						
Asthma	0.82	(0.69, 0.97)	-0.2045	0.0524	9.47E-05	3.98E-03
COPD (Chronic Obstructive Pulmonary Disease)	0.88	(0.58, 1.34)	-0.1281	0.1290	3.21E-01	1.00E+00
Cancer treated in the past year	0.83	(0.51, 1.34)	-0.1877	0.1488	2.07E-01	1.00E+00
Cardiovascular disease	0.94	(0.69, 1.28)	-0.0598	0.0944	5.27E-01	1.00E+00
Chronic kidney disease	0.78	(0.44, 1.40)	-0.2475	0.1791	1.67E-01	1.00E+00
Diabetes	1.10	(0.88, 1.36)	0.0922	0.0673	1.71E-01	1.00E+00
Hypertension	0.90	(0.76, 1.05)	-0.1097	0.0499	2.80E-02	1.00E+00
Other	0.99	(0.77, 1.28)	-0.0080	0.0790	9.20E-01	1.00E+00
Other autoimmune disease	0.87	(0.71, 1.07)	-0.1382	0.0636	2.97E-02	1.00E+00
Other immunodeficiency disorder	0.69	(0.42, 1.11)	-0.3764	0.1496	1.19E-02	4.99E-01

Other lung condition	0.67	(0.44, 1.00)	-0.4064	0.1248	1.13E-03	4.76E-02
Any	0.81	(0.71, 0.92)	-0.2092	0.0405	2.32E-07	9.76E-06
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	0.99	(0.84, 1.16)	-0.0113	0.0502	8.23E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.04	(0.84, 1.28)	0.0390	0.0649	5.47E-01	1.00E+00
obesity III (BMI >= 40)	1.01	(0.80, 1.28)	0.0097	0.0724	8.94E-01	1.00E+00
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	1.36	(1.19, 1.55)	0.3039	0.0409	1.09E-13	4.57E-12
SYMPTOMS						
Abdominal pain	1.00	(0.70, 1.44)	0.0048	0.1108	9.65E-01	1.00E+00
Body aches	1.29	(0.95, 1.74)	0.2508	0.0941	7.72E-03	3.24E-01
Change in taste or smell	6.68	(4.75, 9.39)	1.8991	0.1052	6.77E-73	2.84E-71
Chills	1.35	(1.01, 1.82)	0.3014	0.0912	9.56E-04	4.02E-02
Cough producing phlegm	0.90	(0.65, 1.23)	-0.1098	0.0986	2.65E-01	1.00E+00
Diarrhea	1.16	(0.85, 1.59)	0.1522	0.0970	1.17E-01	1.00E+00
Dry cough	1.05	(0.78, 1.40)	0.0442	0.0912	6.28E-01	1.00E+00
Feeling tired or fatigue	1.35	(0.92, 2.00)	0.3029	0.1202	1.17E-02	4.91E-01
Fever	1.52	(1.13, 2.05)	0.4189	0.0916	4.76E-06	2.00E-04
Headache	1.02	(0.74, 1.40)	0.0218	0.0977	8.24E-01	1.00E+00
Nasal congestion	0.69	(0.52, 0.93)	-0.3651	0.0918	6.93E-05	2.91E-03
Nausea or vomiting	0.96	(0.67, 1.38)	-0.0401	0.1128	7.22E-01	1.00E+00
Runny nose	0.57	(0.42, 0.77)	-0.5690	0.0958	2.83E-09	1.19E-07
Shortness of breath	1.30	(0.96, 1.76)	0.2607	0.0934	5.22E-03	2.19E-01
Sore throat	0.47	(0.34, 0.64)	-0.7609	0.0951	1.33E-15	5.60E-14
	1	1			1	l

110

Adjusted odds ratios for a positive COVID-19 test were calculated among survey participants

reporting a test result (positive or negative) based on the self-reported response to the following question: "Have you been swab tested for COVID-19, commonly referred to as coronavirus?" The

following groups served as reference populations for the odds ratio calculations: European genetic

ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30,

116 Obesity). Note that symptoms odds ratios were calculated in a binary fashion among symptomatic

- 117 customers only (Methods). Here, odds ratios were adjusted for four known exposures (Y/N if any),
- age, and genetic sex (Supplementary Table 2 and Methods).

119

## 121 Supplementary Table 8. Unadjusted risk factor odds ratios for a known "direct" COVID-

## 122 **19 exposure**

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.80	(1.54, 2.12)	0.5896	0.0519	6.64E-30	1.66E-28
Ages 30-49	1.45	(1.31, 1.60)	0.3725	0.0325	2.00E-30	5.00E-29
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	0.32	(0.28, 0.37)	-1.1427	0.0437	0.00E+00	0.00E+00
GENETIC ANCESTRY				l		
Admixed African-European	1.49	(1.23, 1.82)	0.4012	0.0639	3.32E-10	8.31E-09
European	1.00		0.0000		nan	nan
Admixed Amerindian	1.40	(1.21, 1.62)	0.3384	0.0476	1.13E-12	2.82E-11
Other	1.17	(1.05, 1.31)	0.1584	0.0365	1.47E-05	3.67E-04
EXPOSURE				T		
Biological relative tested positive	4.43	(3.79, 5.18)	1.4888	0.0503	1.39E-192	3.48E-191
Healthcare worker directly exposed	11.53	(10.16, 13.08)	2.4450	0.0408	0.00E+00	0.00E+00
Household member tested positive	22.53	(17.88, 28.38)	3.1148	0.0747	0.00E+00	0.00E+00
HEALTH CONDITIONS						
Asthma	1.02	(0.92, 1.14)	0.0216	0.0353	5.40E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	0.44	(0.33, 0.57)	-0.8297	0.0875	0.00E+00	0.00E+00
Cancer treated in the past year	0.36	(0.26, 0.49)	-1.0310	0.1012	0.00E+00	0.00E+00
Cardiovascular disease	0.50	(0.41, 0.61)	-0.6880	0.0647	0.00E+00	0.00E+00
Chronic kidney disease	0.39	(0.27, 0.57)	-0.9295	0.1182	3.77E-15	9.44E-14
Diabetes	0.63	(0.54, 0.73)	-0.4656	0.0473	0.00E+00	0.00E+00
Hypertension	0.73	(0.66, 0.81)	-0.3181	0.0332	0.00E+00	0.00E+00
Other	0.99	(0.84, 1.18)	-0.0080	0.0556	8.86E-01	1.00E+00
Other autoimmune disease	0.87	(0.76, 0.99)	-0.1421	0.0424	8.06E-04	2.02E-02
Other immunodeficiency disorder	0.87	(0.65, 1.17)	-0.1389	0.0953	1.45E-01	1.00E+00
Other lung condition	0.62	(0.48, 0.78)	-0.4859	0.0778	4.22E-10	1.05E-08
Any	0.71	(0.65, 0.78)	-0.3393	0.0276	0.00E+00	0.00E+00

OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.03	(0.93, 1.15)	0.0338	0.0350	3.35E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.03	(0.90, 1.19)	0.0343	0.0456	4.52E-01	1.00E+00
obesity III (BMI >= 40)	1.10	(0.94, 1.28)	0.0927	0.0499	6.31E-02	1.00E+00
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	0.96	(0.87, 1.05)	-0.0443	0.0295	1.33E-01	1.00E+00

125 Unadjusted odds ratios for a known "direct" exposure to COVID-19 were calculated based on the

126 self-reported response to the following question: "Have you been directly exposed to someone

127 who has tested positive for COVID-19?" The following groups served as reference populations

128 for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age),

129 Female (Genetic Sex), and Not Obese (BMI < 30, Obesity).

### 144 Supplementary Table 9. Unadjusted risk factor odds ratios for a household case(s) of

145 **COVID-19** 

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.44	(1.15, 1.79)	0.3623	0.0715	4.01E-07	1.00E-05
Ages 30-49	0.98	(0.84, 1.14)	-0.0204	0.0488	6.76E-01	1.00E+00
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	0.50	(0.41, 0.61)	-0.6882	0.0641	0.00E+00	0.00E+00
GENETIC ANCESTRY						
Admixed African-European	1.35	(1.00, 1.81)	0.2971	0.0954	1.84E-03	4.60E-02
European	1.00		0.0000		nan	nan
Admixed Amerindian	1.95	(1.60, 2.37)	0.6686	0.0634	5.56E-26	1.39E-24
Other	1.23	(1.04, 1.47)	0.2107	0.0557	1.56E-04	3.90E-03
EXPOSURE						
Biological relative tested positive	14.32	(12.30, 16.67)	2.6615	0.0491	0.00E+00	0.00E+00
Directly exposed to someone who tested positive	22.53	(17.88, 28.38)	3.1148	0.0747	0.00E+00	0.00E+00
Healthcare worker directly exposed	1.11	(0.94, 1.32)	0.1073	0.0540	4.71E-02	1.00E+00
HEALTH CONDITIONS						
Asthma	0.91	(0.77, 1.07)	-0.0975	0.0549	7.59E-02	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	0.58	(0.38, 0.89)	-0.5405	0.1363	7.31E-05	1.83E-03
Cancer treated in the past year	0.44	(0.26, 0.75)	-0.8217	0.1735	2.19E-06	5.48E-05
Cardiovascular disease	0.68	(0.50, 0.93)	-0.3795	0.0988	1.23E-04	3.07E-03
Chronic kidney disease	0.53	(0.30, 0.97)	-0.6255	0.1911	1.06E-03	2.66E-02
Diabetes	0.89	(0.72, 1.10)	-0.1187	0.0701	9.02E-02	1.00E+00
Hypertension	0.80	(0.69, 0.94)	-0.2182	0.0516	2.31E-05	5.77E-04
Other	0.93	(0.72, 1.21)	-0.0673	0.0845	4.26E-01	1.00E+00
Other autoimmune disease	0.85	(0.69, 1.04)	-0.1684	0.0667	1.16E-02	2.90E-01
Other immunodeficiency disorder	0.87	(0.56, 1.37)	-0.1357	0.1453	3.50E-01	1.00E+00
Other lung condition	0.63	(0.42, 0.94)	-0.4620	0.1292	3.48E-04	8.70E-03
Any	0.74	(0.65, 0.84)	-0.3047	0.0423	5.80E-13	1.45E-11

OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.05	(0.89, 1.23)	0.0460	0.0533	3.88E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.01	(0.81, 1.25)	0.0064	0.0704	9.28E-01	1.00E+00
obesity III (BMI >= 40)	1.04	(0.82, 1.32)	0.0374	0.0769	6.27E-01	1.00E+00
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	1.18	(1.03, 1.36)	0.1688	0.0438	1.16E-04	2.89E-03

148 Unadjusted odds ratios for a household case(s) of COVID-19 were calculated based on the self-

149 reported response to the following question: "Has someone in your household tested positive for

150 COVID-19?" The following groups served as reference populations for the odds ratio calculations:

151 European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not

152 Obese (BMI < 30, Obesity).

### 166 Supplementary Table 10. Unadjusted risk factor odds ratios for a COVID-19 case(s)

### 167 **amongst close biological relatives (parent, grandparent, child, or sibling)**

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINA L)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.48	(1.18, 1.86)	0.3934	0.0730	7.16E-08	1.79E-06
Ages 30-49	1.02	(0.88, 1.19)	0.0222	0.0502	6.59E-01	1.00E+00
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	0.70	(0.58, 0.85)	-0.3523	0.0605	5.90E-09	1.47E-07
GENETIC ANCESTRY					l	
Admixed African-European	1.69	(1.28, 2.22)	0.5221	0.0896	5.62E-09	1.41E-07
European	1.00		0.0000		nan	nan
Admixed Amerindian	2.08	(1.71, 2.53)	0.7333	0.0634	5.85E-31	1.46E-29
Other	1.42	(1.20, 1.68)	0.3472	0.0547	2.14E-10	5.34E-09
EXPOSURE					li -	
Directly exposed to someone who tested positive	4.43	(3.79, 5.18)	1.4888	0.0503	1.39E-192	3.48E-191
Healthcare worker directly exposed	1.04	(0.87, 1.23)	0.0384	0.0558	4.91E-01	1.00E+00
Household member tested positive	14.32	(12.30, 16.67)	2.6615	0.0491	0.00E+00	0.00E+00
HEALTH CONDITIONS					l	
Asthma	0.98	(0.82, 1.16)	-0.0245	0.0547	6.54E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	0.68	(0.46, 1.02)	-0.3791	0.1293	3.37E-03	8.42E-02
Cancer treated in the past year	0.60	(0.37, 0.97)	-0.5105	0.1542	9.33E-04	2.33E-02
Cardiovascular disease	0.77	(0.57, 1.04)	-0.2600	0.0959	6.72E-03	1.68E-01
Chronic kidney disease	0.52	(0.28, 0.95)	-0.6619	0.1977	8.12E-04	2.03E-02
Diabetes	1.04	(0.84, 1.28)	0.0368	0.0677	5.86E-01	1.00E+00
Hypertension	0.88	(0.75, 1.03)	-0.1281	0.0513	1.25E-02	3.12E-01
Other	1.03	(0.80, 1.33)	0.0297	0.0829	7.20E-01	1.00E+00
Other autoimmune disease	0.90	(0.73, 1.10)	-0.1057	0.0663	1.11E-01	1.00E+00
Other immunodeficiency disorder	0.99	(0.65, 1.53)	-0.0065	0.1394	9.63E-01	1.00E+00
Other lung condition	0.96	(0.69, 1.36)	-0.0368	0.1104	7.39E-01	1.00E+00
Any	0.85	(0.74, 0.97)	-0.1668	0.0429	1.02E-04	2.55E-03

OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.03	(0.87, 1.22)	0.0327	0.0541	5.45E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	0.88	(0.70, 1.11)	-0.1292	0.0748	8.41E-02	1.00E+00
obesity III (BMI >= 40)	1.10	(0.87, 1.39)	0.0945	0.0761	2.14E-01	1.00E+00
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	0.87	(0.75, 1.00)	-0.1404	0.0462	2.39E-03	5.99E-02

170 Unadjusted odds ratios for a case(s) of COVID-19 among close biological relatives (grandparent,

171 parent, child, or sibling) were calculated based on the self-reported response to the following 172 question: "Have any of your biological relatives tested positive for COVID-19? Select all that

apply." The following groups served as reference populations for the odds ratio calculations:
 European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not

175 Obese (BMI < 30, Obesity).

### 189 Supplementary Table 11. Unadjusted risk factor odds ratios for COVID-19 hospitalization

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.42	(0.21, 0.83)	-0.8793	0.2143	4.06E-05	1.71E-03
Ages 30-49	0.54	(0.36, 0.81)	-0.6143	0.1246	8.24E-07	3.46E-05
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	1.70	(1.13, 2.56)	0.5325	0.1263	2.49E-05	1.05E-03
GENETIC ANCESTRY						
Admixed African-European	1.44	(0.78, 2.65)	0.3625	0.1884	5.43E-02	1.00E+00
European	1.00		0.0000		nan	nan
Admixed Amerindian	0.77	(0.44, 1.36)	-0.2579	0.1745	1.39E-01	1.00E+00
Other	0.91	(0.59, 1.40)	-0.0964	0.1335	4.70E-01	1.00E+00
EXPOSURE						
Any	0.74	(0.46, 1.19)	-0.3048	0.1483	3.98E-02	1.00E+00
Biological relative tested positive	1.17	(0.81, 1.69)	0.1550	0.1136	1.73E-01	1.00E+00
Directly exposed to someone who tested positive	0.63	(0.42, 0.96)	-0.4595	0.1279	3.28E-04	1.38E-02
Healthcare worker directly exposed	0.53	(0.34, 0.84)	-0.6317	0.1423	9.09E-06	3.82E-04
Household member tested positive	0.91	(0.65, 1.27)	-0.0971	0.1033	3.47E-01	1.00E+00
HEALTH CONDITIONS						
Asthma	1.42	(0.95, 2.13)	0.3525	0.1249	4.77E-03	2.00E-01
COPD (Chronic Obstructive Pulmonary Disease)	3.48	(1.65, 7.32)	1.2469	0.2296	5.64E-08	2.37E-06
Cancer treated in the past year	3.13	(1.29, 7.57)	1.1396	0.2730	2.99E-05	1.26E-03
Cardiovascular disease	2.82	(1.61, 4.96)	1.0374	0.1740	2.50E-09	1.05E-07
Chronic kidney disease	8.74	(3.44, 22.21)	2.1684	0.2876	4.71E-14	1.98E-12
Diabetes	3.03	(1.98, 4.63)	1.1085	0.1311	2.78E-17	1.17E-15
Hypertension	2.01	(1.41, 2.88)	0.7002	0.1105	2.37E-10	9.96E-09
Other	1.65	(0.93, 2.93)	0.5038	0.1767	4.35E-03	1.83E-01
Other autoimmune disease	1.32	(0.81, 2.17)	0.2811	0.1523	6.49E-02	1.00E+00
Other immunodeficiency disorder	1.98	(0.77, 5.09)	0.6826	0.2915	1.92E-02	8.05E-01
Other lung condition	2.84	(1.32, 6.10)	1.0423	0.2364	1.04E-05	4.35E-04

Any	2.70	(1.90, 3.83)	0.9919	0.1081	4.43E-20	1.86E-18
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.41	(0.94, 2.12)	0.3418	0.1258	6.61E-03	2.78E-01
obesity II (BMI >= 35 and BMI < 40)	1.21	(0.70, 2.09)	0.1883	0.1693	2.66E-01	1.00E+00
obesity III (BMI >= 40)	1.62	(0.93, 2.83)	0.4820	0.1719	5.04E-03	2.12E-01
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	1.27	(0.92, 1.77)	0.2418	0.1015	1.72E-02	7.22E-01
SYMPTOMS						7.22E-01
Abdominal pain	1.76	(1.23, 2.52)	0.5638	0.1112	3.92E-07	1.65E-05
Body aches	1.39	(0.96, 2.02)	0.3309	0.1142	3.75E-03	1.57E-01
Change in taste or smell	0.77	(0.55, 1.07)	-0.2657	0.1039	1.05E-02	4.42E-01
Chills	1.82	(1.29, 2.57)	0.5991	0.1061	1.65E-08	6.92E-07
Cough producing phlegm	1.56	(1.11, 2.20)	0.4474	0.1054	2.19E-05	9.18E-04
Diarrhea	2.12	(1.52, 2.95)	0.7521	0.1021	1.75E-13	7.35E-12
Dry cough	2.59	(1.81, 3.71)	0.9528	0.1104	6.26E-18	2.63E-16
Feeling tired or fatigue	2.54	(1.35, 4.78)	0.9335	0.1949	1.68E-06	7.04E-05
Fever	3.33	(2.26, 4.90)	1.2032	0.1192	5.93E-24	2.49E-22
Headache	0.89	(0.63, 1.26)	-0.1125	0.1063	2.90E-01	1.00E+00
Nasal congestion	0.94	(0.67, 1.31)	-0.0610	0.1030	5.54E-01	1.00E+00
Nausea or vomiting	2.26	(1.58, 3.23)	0.8156	0.1104	1.52E-13	6.39E-12
Runny nose	1.09	(0.76, 1.56)	0.0831	0.1118	4.57E-01	1.00E+00
Shortness of breath	7.52	(4.92, 11.49)	2.0172	0.1309	1.48E-53	6.21E-52
Sore throat	1.04	(0.72, 1.50)	0.0386	0.1127	7.32E-01	1.00E+00

191

192 Unadjusted odds ratios for hospitalization due to COVID-19 infection were calculated among 193 those reporting a positive COVID-19 test result. The following groups served as reference 194 populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages 195 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms 196 odds ratios were calculated in a binary fashion among symptomatic customers only (Methods).

### 198 Supplementary Table 12. Risk factor odds ratios for COVID-19 hospitalization, adjusted

### 199 for health conditions, obesity, age, and sex

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.56	(0.26, 1.20)	-0.5815	0.2359	1.37E-02	5.75E-01
Ages 30-49	0.60	(0.39, 0.92)	-0.5110	0.1333	1.26E-04	5.28E-03
Ages 50-64	1.00		0.0000		nan	nan
Ages 65+	1.60	(1.02, 2.51)	0.4713	0.1381	6.43E-04	2.70E-02
GENETIC ANCESTRY						
Admixed African-European	1.57	(0.81, 3.03)	0.4513	0.2026	2.59E-02	1.00E+00
European	1.00		0.0000		nan	nan
Admixed Amerindian	1.11	(0.59, 2.07)	0.1035	0.1922	5.90E-01	1.00E+00
Other	0.95	(0.59, 1.54)	-0.0493	0.1490	7.41E-01	1.00E+00
EXPOSURE						
Any	0.81	(0.48, 1.39)	-0.2060	0.1653	2.13E-01	1.00E+00
Biological relative tested positive	1.16	(0.78, 1.74)	0.1498	0.1248	2.30E-01	1.00E+00
Directly exposed to someone who tested positive	0.68	(0.43, 1.07)	-0.3870	0.1397	5.61E-03	2.36E-01
Healthcare worker directly exposed	0.63	(0.38, 1.04)	-0.4685	0.1567	2.79E-03	1.17E-01
Household member tested positive	0.88	(0.62, 1.26)	-0.1245	0.1109	2.62E-01	1.00E+00
HEALTH CONDITIONS						
Asthma	1.42	(0.92, 2.20)	0.3537	0.1343	8.42E-03	3.54E-01
COPD (Chronic Obstructive Pulmonary Disease)	2.25	(0.99, 5.14)	0.8123	0.2542	1.40E-03	5.87E-02
Cancer treated in the past year	1.90	(0.72, 5.04)	0.6422	0.3012	3.30E-02	1.00E+00
Cardiovascular disease	1.67	(0.90, 3.11)	0.5139	0.1914	7.24E-03	3.04E-01
Chronic kidney disease	5.62	(2.10, 15.03)	1.7267	0.3034	1.26E-08	5.30E-07
Diabetes	2.22	(1.39, 3.55)	0.7988	0.1442	3.06E-08	1.28E-06
Hypertension	1.32	(0.88, 1.97)	0.2757	0.1239	2.61E-02	1.00E+00
Other	1.47	(0.80, 2.71)	0.3878	0.1875	3.86E-02	1.00E+00
Other autoimmune disease	1.41	(0.83, 2.40)	0.3461	0.1635	3.42E-02	1.00E+00
Other immunodeficiency disorder	1.83	(0.68, 4.93)	0.6032	0.3062	4.88E-02	1.00E+00

Other lung condition	1.87	(0.83, 4.22)	0.6242	0.2514	1.30E-02	5.47E-01
Any	2.08	(1.42, 3.04)	0.7333	0.1172	3.93E-10	1.65E-08
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.19	(0.77, 1.82)	0.1707	0.1323	1.97E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.13	(0.64, 2.00)	0.1249	0.1750	4.75E-01	1.00E+00
obesity III (BMI >= 40)	1.59	(0.88, 2.87)	0.4631	0.1821	1.10E-02	4.62E-01
Not obese	1.00		0.0000		nan	nan
GENETIC SEX						
Female	1.00		0.0000		nan	nan
Male	1.22	(0.85, 1.74)	0.1960	0.1103	7.57E-02	1.00E+00
SYMPTOMS						
Abdominal pain	1.66	(1.12, 2.46)	0.5086	0.1214	2.81E-05	1.18E-03
Body aches	1.44	(0.96, 2.15)	0.3646	0.1240	3.27E-03	1.37E-01
Change in taste or smell	0.89	(0.62, 1.29)	-0.1159	0.1139	3.09E-01	1.00E+00
Chills	1.94	(1.33, 2.82)	0.6609	0.1156	1.07E-08	4.51E-07
Cough producing phlegm	1.41	(0.97, 2.05)	0.3470	0.1150	2.54E-03	1.07E-01
Diarrhea	2.23	(1.55, 3.20)	0.8014	0.1120	8.21E-13	3.45E-11
Dry cough	2.49	(1.69, 3.67)	0.9114	0.1196	2.55E-14	1.07E-12
Feeling tired or fatigue	2.81	(1.38, 5.74)	1.0333	0.2203	2.73E-06	1.15E-04
Fever	3.49	(2.29, 5.34)	1.2510	0.1309	1.24E-21	5.19E-20
Headache	1.05	(0.72, 1.54)	0.0487	0.1180	6.80E-01	1.00E+00
Nasal congestion	0.93	(0.65, 1.34)	-0.0698	0.1122	5.34E-01	1.00E+00
Nausea or vomiting	2.41	(1.62, 3.59)	0.8801	0.1230	8.38E-13	3.52E-11
Runny nose	0.93	(0.62, 1.39)	-0.0710	0.1232	5.65E-01	1.00E+00
Shortness of breath	8.20	(5.14, 13.08)	2.1042	0.1440	2.37E-48	9.96E-47
Sore throat	1.11	(0.75, 1.66)	0.1074	0.1224	3.80E-01	1.00E+00

201

Adjusted odds ratios for hospitalization due to COVID-19 infection were calculated among those reporting a positive COVID-19 test result. The following groups served as reference populations

for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age),

205 Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms odds ratios were

206 calculated in a binary fashion among symptomatic customers only (Methods). Here, odds ratios

were adjusted for age, sex, comorbitidies (Y/N if any), and obesity (Y/N if BMI > 30, Methods).

# 209 Supplementary Table 13. Unadjusted risk factor odds ratios for progression of COVID-19

#### 210 to a critical case.

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.35	(0.13, 0.95)	-1.0599	0.3114	6.64E-04	2.79E-02
Ages 30-49	0.55	(0.32, 0.94)	-0.5983	0.1652	2.92E-04	1.23E-02
Ages 50-64	1		0		nan	nan
Ages 65+	1.65	(0.97, 2.80)	0.5001	0.1632	2.19E-03	9.18E-02
GENETIC ANCESTRY						
Admixed African-European	2.07	(1.03, 4.17)	0.7269	0.2166	7.91E-04	3.32E-02
European	1		0		nan	nan
Admixed Amerindian	0.75	(0.35, 1.62)	-0.2871	0.2377	2.27E-01	1.00E+00
Other	0.82	(0.45, 1.49)	-0.2044	0.1853	2.70E-01	1.00E+00
EXPOSURE						
Any	0.77	(0.40, 1.45)	-0.2675	0.1981	1.77E-01	1.00E+00
Biological relative tested positive	1.15	(0.70, 1.86)	0.1356	0.1502	3.67E-01	1.00E+00
Directly exposed to someone who tested positive	0.59	(0.34, 1.01)	-0.5348	0.1691	1.56E-03	6.55E-02
Healthcare worker directly exposed	0.53	(0.29, 0.99)	-0.6277	0.1912	1.03E-03	4.31E-02
Household member tested positive	1.00	(0.64, 1.55)	-0.0001	0.1353	1.00E+00	1.00E+00
HEALTH CONDITIONS						
Asthma	1.26	(0.74, 2.17)	0.235	0.1672	1.60E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	3.76	(1.57, 9.02)	1.3257	0.2696	8.79E-07	3.69E-05
Cancer treated in the past year	2.07	(0.60, 7.12)	0.7266	0.3814	5.68E-02	1.00E+00
Cardiovascular disease	2.44	(1.17, 5.05)	0.8906	0.2251	7.60E-05	3.19E-03
Chronic kidney disease	8.00	(2.92, 21.91)	2.0794	0.3109	2.26E-11	9.47E-10
Diabetes	3.14	(1.85, 5.32)	1.1431	0.1629	2.29E-12	9.61E-11
Hypertension	2.06	(1.30, 3.27)	0.7214	0.1425	4.15E-07	1.74E-05
Other	1.07	(0.45, 2.54)	0.0649	0.2674	8.08E-01	1.00E+00
Other autoimmune disease	1.35	(0.71, 2.55)	0.2973	0.1973	1.32E-01	1.00E+00
Other immunodeficiency disorder	1.81	(0.53, 6.16)	0.5907	0.3788	1.19E-01	1.00E+00

Other lung condition	3.29	(1.35, 8.00)	1.1909	0.274	1.39E-05	5.82E-04
Any	2.85	(1.78, 4.57)	1.0485	0.1452	5.22E-13	2.19E-11
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.31	(0.76, 2.27)	0.2714	0.1696	1.09E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.16	(0.56, 2.43)	0.1525	0.2275	5.03E-01	1.00E+00
obesity III (BMI >= 40)	2.06	(1.05, 4.02)	0.7211	0.2071	4.98E-04	2.09E-02
Not obese	1		0		nan	nan
GENETIC SEX						
Female	1		0		nan	nan
Male	1.54	(1.00, 2.37)	0.4342	0.1325	1.05E-03	4.42E-02
SYMPTOMS						
Abdominal pain	1.95	(1.23, 3.08)	0.666	0.1413	2.45E-06	1.03E-04
Body aches	1.58	(0.95, 2.60)	0.4547	0.1546	3.27E-03	1.37E-01
Change in taste or smell	0.79	(0.51, 1.23)	-0.2319	0.1358	8.79E-02	1.00E+00
Chills	2.04	(1.28, 3.23)	0.7106	0.1423	5.96E-07	2.50E-05
Cough producing phlegm	1.83	(1.18, 2.84)	0.6063	0.1351	7.24E-06	3.04E-04
Diarrhea	2.48	(1.61, 3.84)	0.9102	0.1339	1.08E-11	4.53E-10
Dry cough	2.67	(1.66, 4.31)	0.9836	0.1474	2.49E-11	1.04E-09
Feeling tired or fatigue	2.55	(1.09, 5.97)	0.9344	0.2628	3.77E-04	1.58E-02
Fever	3.52	(2.08, 5.96)	1.2595	0.1622	8.00E-15	3.36E-13
Headache	0.97	(0.61, 1.52)	-0.0356	0.1402	8.00E-01	1.00E+00
Nasal congestion	1.06	(0.69, 1.64)	0.0592	0.1337	6.58E-01	1.00E+00
Nausea or vomiting	2.27	(1.44, 3.60)	0.8217	0.1415	6.30E-09	2.64E-07
Runny nose	1.31	(0.83, 2.07)	0.2696	0.1415	5.68E-02	1.00E+00
Shortness of breath	11.55	(5.91, 22.59)	2.4466	0.2069	2.93E-32	1.23E-30
Sore throat	1.45	(0.92, 2.29)	0.374	0.1396	7.40E-03	3.11E-01

212

213 Unadjusted odds ratios for progression of COVID-19 infection to a critical, life-threatening illness

214 were calculated among those reporting a positive COVID-19 test result. The following groups

215 served as reference populations for the odds ratio calculations: European genetic ancestry (Genetic

216 Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note

that symptoms odds ratios were calculated in a binary fashion among symptomatic customers only

218 (Methods).

## 220 Supplementary Table 14. Risk factor odds ratios for progression of COVID-19 to a critical

221 case, adjusted for health conditions, obesity, age, and sex.

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.46	(0.15, 1.45)	-0.7675	0.3506	2.86E-02	1.00E+00
Ages 30-49	0.67	(0.38, 1.17)	-0.4033	0.1735	2.01E-02	8.45E-01
Ages 50-64	1		0		nan	nan
Ages 65+	1.51	(0.85, 2.69)	0.41	0.1785	2.16E-02	9.07E-01
GENETIC ANCESTRY						
Admixed African-European	2.34	(1.11, 4.95)	0.8516	0.2308	2.25E-04	9.43E-03
European	1		0		nan	nan
Admixed Amerindian	1.12	(0.49, 2.56)	0.1145	0.2548	6.53E-01	1.00E+00
Other	0.85	(0.44, 1.65)	-0.164	0.206	4.26E-01	1.00E+00
EXPOSURE						
Any	0.83	(0.41, 1.67)	-0.1862	0.2163	3.89E-01	1.00E+00
Biological relative tested positive	1.23	(0.73, 2.08)	0.2104	0.1609	1.91E-01	1.00E+00
Directly exposed to someone who tested positive	0.62	(0.34, 1.13)	-0.4747	0.183	9.49E-03	3.98E-01
Healthcare worker directly exposed	0.62	(0.31, 1.24)	-0.4703	0.2116	2.63E-02	1.00E+00
Household member tested positive	1.01	(0.63, 1.60)	0.0068	0.1434	9.62E-01	1.00E+00
HEALTH CONDITIONS						
Asthma	1.24	(0.69, 2.22)	0.2124	0.1806	2.40E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	2.39	(0.90, 6.36)	0.8704	0.302	3.95E-03	1.66E-01
Cancer treated in the past year	1.08	(0.26, 4.55)	0.0784	0.4429	8.59E-01	1.00E+00
Cardiovascular disease	1.42	(0.64, 3.15)	0.3485	0.2469	1.58E-01	1.00E+00
Chronic kidney disease	4.88	(1.67, 14.30)	1.586	0.3314	1.70E-06	7.13E-05
Diabetes	2.16	(1.20, 3.89)	0.7699	0.1816	2.23E-05	9.38E-04
Hypertension	1.34	(0.80, 2.24)	0.2903	0.1599	6.95E-02	1.00E+00
Other	1.19	(0.49, 2.88)	0.1765	0.2714	5.16E-01	1.00E+00
Other autoimmune disease	1.55	(0.78, 3.06)	0.4368	0.2105	3.80E-02	1.00E+00
Other immunodeficiency disorder	1.82	(0.52, 6.31)	0.5962	0.3844	1.21E-01	1.00E+00

Other lung condition	2.09	(0.80, 5.47)	0.7376	0.2965	1.29E-02	5.40E-01
Any	2.22	(1.33, 3.69)	0.7959	0.157	4.00E-07	1.68E-05
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.09	(0.62, 1.93)	0.0882	0.1761	6.17E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.06	(0.50, 2.26)	0.0605	0.2334	7.96E-01	1.00E+00
obesity III (BMI >= 40)	1.95	(0.96, 3.98)	0.6695	0.2196	2.29E-03	9.64E-02
Not obese	1		0		nan	nan
GENETIC SEX						
Female	1		0		nan	nan
Male	1.5	(0.95, 2.37)	0.4041	0.142	4.42E-03	1.85E-01
SYMPTOMS						
Abdominal pain	2.03	(1.24, 3.32)	0.7095	0.1514	2.77E-06	1.16E-04
Body aches	1.88	(1.08, 3.27)	0.6321	0.1707	2.13E-04	8.95E-03
Change in taste or smell	1.03	(0.63, 1.66)	0.025	0.1485	8.66E-01	1.00E+00
Chills	2.22	(1.35, 3.66)	0.7975	0.1542	2.31E-07	9.70E-06
Cough producing phlegm	1.69	(1.05, 2.70)	0.5233	0.1452	3.14E-04	1.32E-02
Diarrhea	2.74	(1.71, 4.39)	1.0077	0.1457	4.58E-12	1.92E-10
Dry cough	2.73	(1.62, 4.59)	1.0041	0.1601	3.60E-10	1.51E-08
Feeling tired or fatigue	2.86	(1.10, 7.40)	1.05	0.2938	3.51E-04	1.48E-02
Fever	3.34	(1.91, 5.85)	1.2074	0.1726	2.65E-12	1.11E-10
Headache	1.18	(0.72, 1.95)	0.1678	0.1537	2.75E-01	1.00E+00
Nasal congestion	1.12	(0.70, 1.78)	0.1106	0.1435	4.41E-01	1.00E+00
Nausea or vomiting	2.72	(1.65, 4.49)	0.9997	0.1547	1.03E-10	4.31E-09
Runny nose	1.19	(0.72, 1.95)	0.1704	0.153	2.65E-01	1.00E+00
Shortness of breath	12.87	(6.18, 26.81)	2.5549	0.2265	1.62E-29	6.79E-28
Sore throat	1.65	(1.01, 2.68)	0.4991	0.1503	9.01E-04	3.79E-02

223

Adjusted odds ratios for progression of COVID-19 infection to a critical, life-threatening illness were calculated among those reporting a positive COVID-19 test result. The following groups

served as reference populations for the odds ratio calculations: European genetic ancestry (Genetic

Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note

that symptoms odds ratios were calculated in a binary fashion among symptomatic customers only

229 (Methods). Here, odds ratios were adjusted for age, sex, comorbitidies (Y/N if any), and obesity

230 (Y/N if BMI > 30, Methods).

## 231 Supplementary Table 15. Unadjusted risk factor odds ratios for COVID-19 susceptibility

### 232 (training dataset)

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	1.6	(1.21, 2.11)	0.4693	0.0857	4.42E-08	1.86E-06
Ages 30-49	1.11	(0.92, 1.34)	0.105	0.0584	7.22E-02	1.00E+00
Ages 50-64	1		0		nan	nan
Ages 65+	0.49	(0.38, 0.63)	-0.7051	0.077	0.00E+00	0.00E+00
GENETIC ANCESTRY				l		
Admixed African-European	1.24	(0.85, 1.81)	0.2158	0.1168	6.47E-02	1.00E+00
European	1		0		nan	nan
Admixed Amerindian	1.59	(1.22, 2.07)	0.462	0.0814	1.36E-08	5.73E-07
Other	1.16	(0.94, 1.44)	0.1516	0.0665	2.27E-02	9.52E-01
EXPOSURE						
Any	9.49	(7.65, 11.77)	2.2503	0.0665	4.79E-251	2.01E-249
Biological relative tested positive	5.74	(4.66, 7.07)	1.7467	0.0644	4.71E-162	1.98E-160
Directly exposed to someone who tested positive	7.63	(6.33, 9.19)	2.0317	0.0576	4.44E-272	1.87E-270
Healthcare worker directly exposed	1.56	(1.29, 1.87)	0.4417	0.0576	1.78E-14	7.47E-13
Household member tested positive	24.28	(19.62, 30.03)	3.1896	0.0657	0.00E+00	0.00E+00
PRE-EXISTING CONDITION						
Asthma	0.81	(0.65, 1.00)	-0.2166	0.0677	1.37E-03	5.75E-02
COPD (Chronic Obstructive Pulmonary Disease)	0.54	(0.31, 0.93)	-0.6217	0.1684	2.22E-04	9.32E-03
Cancer treated in the past year	0.57	(0.32, 1.00)	-0.564	0.1731	1.12E-03	4.71E-02
Cardiovascular disease	0.74	(0.51, 1.06)	-0.3014	0.1122	7.26E-03	3.05E-01
Chronic kidney disease	0.55	(0.28, 1.10)	-0.5938	0.2139	5.49E-03	2.31E-01
Diabetes	0.9	(0.69, 1.17)	-0.105	0.0816	1.98E-01	1.00E+00
Hypertension	0.76	(0.62, 0.93)	-0.2728	0.061	7.64E-06	3.21E-04
Other	0.93	(0.66, 1.31)	-0.0726	0.1049	4.89E-01	1.00E+00
Other autoimmune disease	0.8	(0.61, 1.04)	-0.2241	0.081	5.65E-03	2.37E-01
Other immunodeficiency disorder	0.77	(0.42, 1.40)	-0.2669	0.1854	1.50E-01	1.00E+00
Other lung condition	0.64	(0.39, 1.03)	-0.4524	0.1502	2.59E-03	1.09E-01

Any	0.67	(0.57, 0.79)	-0.3983	0.0498	1.33E-15	5.60E-14
•		(((())))				
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.02	(0.83, 1.25)	0.0212	0.0628	7.35E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.15	(0.94, 1.41)	0.1376	0.0626	2.81E-02	1.00E+00
obesity III (BMI >= 40)	1.13	(0.85, 1.50)	0.12	0.0874	1.70E-01	1.00E+00
Not obese	1		0		nan	nan
GENETIC SEX						
Female	1		0		nan	nan
Male	1.16	(0.98, 1.37)	0.1459	0.0525	5.43E-03	2.28E-01
SYMPTOMS						
Abdominal pain	0.97	(0.64, 1.48)	-0.0303	0.1303	8.16E-01	1.00E+00
Body aches	1.56	(1.09, 2.23)	0.4461	0.1104	5.34E-05	2.24E-03
Change in taste or smell	7.02	(4.67, 10.56)	1.9493	0.1257	2.96E-54	1.24E-52
Chills	1.38	(0.97, 1.96)	0.3211	0.1085	3.08E-03	1.29E-01
Cough producing phlegm	0.93	(0.64, 1.37)	-0.0685	0.1178	5.61E-01	1.00E+00
Diarrhea	1.18	(0.81, 1.72)	0.1672	0.1158	1.49E-01	1.00E+00
Dry cough	1.29	(0.91, 1.84)	0.2578	0.1082	1.72E-02	7.21E-01
Feeling tired or fatigue	1.54	(0.99, 2.42)	0.4341	0.1381	1.67E-03	7.03E-02
Fever	1.54	(1.08, 2.19)	0.4295	0.1088	7.84E-05	3.29E-03
Headache	1.39	(0.97, 2.00)	0.33	0.1118	3.17E-03	1.33E-01
Nasal congestion	0.85	(0.60, 1.21)	-0.1632	0.1081	1.31E-01	1.00E+00
Nausea or vomiting	0.82	(0.53, 1.26)	-0.1979	0.1327	1.36E-01	1.00E+00
Runny nose	0.59	(0.41, 0.86)	-0.5246	0.1137	3.92E-06	1.65E-04
Shortness of breath	1.25	(0.87, 1.79)	0.2219	0.1106	4.48E-02	1.00E+00
Sore throat	0.48	(0.34, 0.69)	-0.7286	0.1117	6.84E-11	2.87E-09
			1	1		1

233

Unadjusted odds ratios for a positive COVID-19 test were calculated among survey participants reporting a test result (positive or negative). The following groups served as reference populations

for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages 50-64 (Age),

Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms odds ratios were

calculated in a binary fashion among symptomatic customers only (Methods).

## 240 Supplementary Table 16. Unadjusted risk factor odds ratios for COVID-19 hospitalization

## 241 (training dataset)

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.53	(0.20, 1.37)	-0.6395	0.2951	3.02E-02	1.00E+00
Ages 30-49	0.5	(0.27, 0.92)	-0.6907	0.1879	2.37E-04	9.95E-03
Ages 50-64	1		0		nan	nan
Ages 65+	1.64	(0.87, 3.08)	0.4956	0.1943	1.07E-02	4.51E-01
GENETIC ANCESTRY						
Admixed African-European	1.19	(0.43, 3.28)	0.176	0.3121	5.73E-01	1.00E+00
European	1		0		nan	nan
Admixed Amerindian	0.77	(0.32, 1.86)	-0.2551	0.2703	3.45E-01	1.00E+00
Other	0.69	(0.34, 1.39)	-0.3752	0.2169	8.37E-02	1.00E+00
EXPOSURE						
Any	0.69	(0.34, 1.39)	-0.3732	0.2174	8.61E-02	1.00E+00
Biological relative tested positive	1.06	(0.60, 1.88)	0.0572	0.1772	7.47E-01	1.00E+00
Directly exposed to someone who tested positive	0.54	(0.29, 0.98)	-0.6207	0.1867	8.86E-04	3.72E-02
Healthcare worker directly exposed	0.57	(0.29, 1.10)	-0.5698	0.2042	5.26E-03	2.21E-01
Household member tested positive	0.88	(0.53, 1.45)	-0.1332	0.1551	3.90E-01	1.00E+00
HEALTH CONDITIONS						
Asthma	1.17	(0.62, 2.19)	0.1555	0.1944	4.24E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	2.95	(0.82, 10.67)	1.083	0.3962	6.27E-03	2.63E-01
Cancer treated in the past year	3.21	(0.88, 11.78)	1.1677	0.4006	3.56E-03	1.49E-01
Cardiovascular disease	2.73	(1.18, 6.28)	1.0036	0.2573	9.62E-05	4.04E-03
Chronic kidney disease	10.82	(2.86, 40.90)	2.3812	0.4103	6.49E-09	2.73E-07
Diabetes	3.21	(1.70, 6.06)	1.1676	0.1957	2.44E-09	1.02E-07
Hypertension	1.68	(0.98, 2.88)	0.5172	0.1664	1.88E-03	7.91E-02
Other	1.63	(0.74, 3.63)	0.4906	0.2463	4.64E-02	1.00E+00
Other autoimmune disease	1.21	(0.58, 2.54)	0.1914	0.2288	4.03E-01	1.00E+00
Other immunodeficiency disorder	0.77	(0.11, 5.53)	-0.2655	0.6094	6.63E-01	1.00E+00

Other lung condition	1.8	(0.50, 6.55)	0.5883	0.3983	1.40E-01	1.00E+00
Any	2.36	(1.41, 3.93)	0.8574	0.1575	5.26E-08	2.21E-06
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.32	(0.74, 2.34)	0.2765	0.1771	1.19E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.08	(0.56, 2.06)	0.0753	0.2001	7.07E-01	1.00E+00
obesity III (BMI >= 40)	1.42	(0.62, 3.26)	0.3505	0.2566	1.72E-01	1.00E+00
Not obese	1		0		nan	nan
GENETIC SEX						
Female	1		0		nan	nan
Male	1.29	(0.79, 2.12)	0.2584	0.1525	9.02E-02	1.00E+00
SYMPTOMS						
Abdominal pain	1.79	(1.04, 3.10)	0.5841	0.1686	5.33E-04	2.24E-02
Body aches	1.6	(0.90, 2.83)	0.4695	0.1765	7.80E-03	3.28E-01
Change in taste or smell	0.83	(0.50, 1.38)	-0.189	0.1582	2.32E-01	1.00E+00
Chills	2.18	(1.29, 3.71)	0.7814	0.1632	1.68E-06	7.07E-05
Cough producing phlegm	1.51	(0.90, 2.53)	0.4096	0.1596	1.03E-02	4.31E-01
Diarrhea	2.04	(1.24, 3.36)	0.7114	0.154	3.87E-06	1.62E-04
Dry cough	2.5	(1.47, 4.28)	0.9179	0.1653	2.80E-08	1.18E-06
Feeling tired or fatigue	4.47	(1.35, 14.73)	1.4965	0.3681	4.79E-05	2.01E-03
Fever	3.06	(1.72, 5.44)	1.1178	0.178	3.36E-10	1.41E-08
Headache	0.87	(0.52, 1.47)	-0.1351	0.16	3.99E-01	1.00E+00
Nasal congestion	0.73	(0.44, 1.23)	-0.3139	0.1595	4.90E-02	1.00E+00
Nausea or vomiting	2.48	(1.45, 4.23)	0.9068	0.1653	4.13E-08	1.74E-06
Runny nose	0.87	(0.49, 1.55)	-0.1355	0.1777	4.46E-01	1.00E+00
Shortness of breath	6.4	(3.49, 11.73)	1.8558	0.187	3.34E-23	1.40E-21
Sore throat	1.03	(0.59, 1.80)	0.0332	0.1717	8.47E-01	1.00E+00
1		1				

243

Unadjusted odds ratios for hospitalization due to COVID-19 infection were calculated among those reporting a positive COVID-19 test result. The following groups served as reference populations for the odds ratio calculations: European genetic ancestry (Genetic Ancestry), Ages

50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note that symptoms

248 odds ratios were calculated in a binary fashion among symptomatic customers only (Methods).

## 250 Supplementary Table 17. Unadjusted risk factor odds ratios for progression of COVID-19

## 251 to a critical case (training dataset)

RISK FACTOR	ODDS RATIO (OR)	OR 95% CI (BONFERRONI)	logOR	logOR S.E.	P-VALUE (NOMINAL)	P-VALUE (BONFERRONI)
AGE						
Ages 18-29	0.48	(0.12, 1.84)	-0.7444	0.4175	7.46E-02	1.00E+00
Ages 30-49	0.61	(0.28, 1.33)	-0.4935	0.2408	4.04E-02	1.00E+00
Ages 50-64	1		0		nan	nan
Ages 65+	1.32	(0.56, 3.12)	0.2779	0.2651	2.95E-01	1.00E+00
GENETIC ANCESTRY						
Admixed African-European	2.2	(0.72, 6.73)	0.7892	0.3445	2.20E-02	9.24E-01
European	1		0		nan	nan
Admixed Amerindian	1.08	(0.36, 3.21)	0.0779	0.3354	8.16E-01	1.00E+00
Other	0.84	(0.34, 2.13)	-0.1692	0.2852	5.53E-01	1.00E+00
EXPOSURE						
Any	0.67	(0.26, 1.72)	-0.3951	0.2884	1.71E-01	1.00E+00
Biological relative tested positive	1.18	(0.56, 2.50)	0.1677	0.2304	4.67E-01	1.00E+00
Directly exposed to someone who tested positive	0.46	(0.20, 1.03)	-0.7835	0.2502	1.74E-03	7.31E-02
Healthcare worker directly exposed	0.61	(0.25, 1.47)	-0.4938	0.2711	6.85E-02	1.00E+00
Household member tested positive	0.99	(0.51, 1.93)	-0.0064	0.2055	9.75E-01	1.00E+00
PRE-EXISTING CONDITION						
Asthma	1.04	(0.44, 2.46)	0.0353	0.2669	8.95E-01	1.00E+00
COPD (Chronic Obstructive Pulmonary Disease)	4.34	(1.06, 17.88)	1.4689	0.4366	7.66E-04	3.22E-02
Cancer treated in the past year	1.66	(0.23, 12.21)	0.5094	0.6149	4.07E-01	1.00E+00
Cardiovascular disease	2.88	(1.03, 8.08)	1.0584	0.318	8.74E-04	3.67E-02
Chronic kidney disease	13.83	(3.59, 53.34)	2.6267	0.4165	2.85E-10	1.20E-08
Diabetes	3.53	(1.61, 7.75)	1.2624	0.2422	1.86E-07	7.82E-06
Hypertension	2.16	(1.09, 4.29)	0.7721	0.2113	2.59E-04	1.09E-02
Other	1.64	(0.58, 4.63)	0.4926	0.3206	1.24E-01	1.00E+00
Other autoimmune disease	1.28	(0.49, 3.36)	0.2478	0.2976	4.05E-01	1.00E+00
Other immunodeficiency disorder	2.16	(0.37, 12.54)	0.7723	0.542	1.54E-01	1.00E+00

Other lung condition	3.74	(1.01, 13.88)	1.3195	0.4045	1.10E-03	4.64E-02
Any	3.13	(1.52, 6.45)	1.1406	0.2233	3.25E-07	1.37E-05
OBESITY						
obesity I (BMI >= 30 and BMI < 35)	1.24	(0.57, 2.68)	0.2116	0.2385	3.75E-01	1.00E+00
obesity II (BMI >= 35 and BMI < 40)	1.12	(0.48, 2.62)	0.1104	0.2632	6.75E-01	1.00E+00
obesity III (BMI >= 40)	1.5	(0.51, 4.38)	0.4053	0.3305	2.20E-01	1.00E+00
Not obese	1		0		nan	nan
GENETIC SEX						
Female	1		0		nan	nan
Male	1.53	(0.80, 2.94)	0.4266	0.2013	3.41E-02	1.00E+00
SYMPTOMS						
Abdominal pain	2.02	(1.01, 4.06)	0.7042	0.2147	1.04E-03	4.37E-02
Body aches	2.16	(0.95, 4.93)	0.7723	0.2541	2.37E-03	9.95E-02
Change in taste or smell	0.73	(0.37, 1.41)	-0.3191	0.2051	1.20E-01	1.00E+00
Chills	2.32	(1.14, 4.72)	0.8403	0.2196	1.30E-04	5.44E-03
Cough producing phlegm	1.89	(0.97, 3.66)	0.6342	0.2046	1.94E-03	8.13E-02
Diarrhea	2.33	(1.21, 4.48)	0.844	0.2021	2.96E-05	1.24E-03
Dry cough	2.69	(1.30, 5.56)	0.9909	0.2238	9.53E-06	4.00E-04
Feeling tired or fatigue	6.27	(0.93, 42.41)	1.8352	0.59	1.87E-03	7.84E-02
Fever	3.33	(1.50, 7.36)	1.2022	0.2449	9.18E-07	3.85E-05
Headache	0.86	(0.44, 1.70)	-0.1487	0.2098	4.78E-01	1.00E+00
Nasal congestion	0.92	(0.48, 1.80)	-0.0791	0.2053	7.00E-01	1.00E+00
Nausea or vomiting	2.43	(1.22, 4.84)	0.8874	0.2129	3.07E-05	1.29E-03
Runny nose	0.95	(0.45, 2.01)	-0.0495	0.2303	8.30E-01	1.00E+00
Shortness of breath	10.57	(3.99, 28.02)	2.3584	0.3007	4.35E-15	1.83E-13
Sore throat	1.27	(0.63, 2.57)	0.2369	0.2177	2.76E-01	1.00E+00
		1			1	1

253

Unadjusted odds ratios for progression of COVID-19 infection to a critical, life-threatening illness
 were calculated among those reporting a positive COVID-19 test result. The following groups
 served as reference populations for the odds ratio calculations: European genetic ancestry (Genetic
 Ancestry), Ages 50-64 (Age), Female (Genetic Sex), and Not Obese (BMI < 30, Obesity). Note</li>

that symptoms odds ratios were calculated in a binary fashion among symptomatic customers only

259 (Methods).

### 261 Supplementary Table 18. Summary of risk factors and performances of different models

#### 262

263

Model	Risk Factors in Final Model	Holdout AUC (95% CI)
Susceptibility– symptoms excluded (Dem + Exp)	sex, aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Healthcare worker directly exposed, Household member tested positive, Household positive case count, Biological relative tested positive, Directly exposed to someone who tested positive	0.84 (0.82, 0.86)
Susceptibility– symptoms included (Dem + Exp + Symp)	sex, Fever, Runny nose, Sore throat, Feeling tired or fatigue, Change in taste or smell, aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Healthcare worker directly exposed, Household member tested positive, Household positive case count, Biological relative tested positive, Directly exposed to someone who tested positive	0.94 (0.92, 0.96)
Susceptibility– symptoms excluded, L1-penalized model across larger set of risk factors	aged 18-29 (Y/N), aged 30-49 (Y/N), aged 65+ (Y/N), Biological relative tested positive, Directly exposed to someone who tested positive, Hypertension, Healthcare worker directly exposed, Household positive case count, Household member tested positive, Health condition (Y/N if any)	0.86 (0.85, 0.87)
Susceptibility– symptoms included, L1-penalized model across larger set of risk factors	aged 18-29 (Y/N), aged 30-49 (Y/N), aged 65+ (Y/N), Biological relative tested positive, Directly exposed to someone who tested positive, Hypertension, Healthcare worker directly exposed, Household positive case count, Household member tested positive, Health condition (Y/N if any), Abdominal pain, Body aches, Change in taste or smell, Chills, Cough producing phlegm, Diarrhea, Dry cough, Feeling tired or fatigue, Fever, Headache, Nasal congestion, Nausea or vomiting, Runny nose, Shortness of breath, Sore throat	0.90 (0.86, 0.94)
Susceptibility– literature- based "minimal" model (HWF Exp + Symp)	Change in taste or smell, Household member tested positive, Directly exposed to someone who tested positive	0.90 (0.88, 0.93)
Susceptibility– literature- based "symptoms-only" model (HWF Symp)		0.87 (0.84, 0.90)
Severity– hospitalization	Fever, Shortness of breath, Dry cough, Sore throat, Chills, Body aches, Change in taste or smell sex, Fever, Shortness of breath, Dry cough, Feeling tired or fatigue, Diarrhea, Obesity III (BMI >=	0.87 (0.84,
	40), aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged $65+$ (Y/N), Health condition (Y/N if any)	0.90)
Severity– hospitalization, L1-penalized model across larger set of risk factors	aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), COPD (Chronic Obstructive Pulmonary Disease), Cancer (treated in the past year), Cardiovascular disease, Chronic kidney disease, Diabetes, Hypertension, Other, Health condition (Y/N if any), Abdominal pain, Chills, Cough producing phlegm, Diarrhea, Dry cough, Feeling tired or fatigue, Fever, Nausea or vomiting, Shortness of breath	0.87 (0.86, 0.88)
Severity– critical case	sex, Fever, Shortness of breath, Dry cough, Feeling tired or fatigue, Diarrhea, Obesity III (BMI >= 40), aged 18-29 (Y/N), aged 30-49 (Y/N), aged 50-64 (Y/N), aged 65+ (Y/N), Health condition (Y/N if any)	0.90 (0.87, 0.93)
Severity– critical case, L1- penalized model across larger set of risk factors	aged 30-49 (Y/N), aged 65+ (Y/N), COPD (Chronic Obstructive Pulmonary Disease), Cardiovascular disease, Chronic kidney disease, Diabetes, Hypertension, Other lung condition, Health condition (Y/N if any), Seasonal flu, sex, Abdominal pain, Body aches, Chills, Cough producing phlegm, Diarrhea, Dry cough, Feeling tired or fatigue, Fever, Nausea or vomiting, Shortness of breath	0.89 (0.87, 0.91)

- 265 Risk factors for models were selected based on literature as well as nominally significant odds
- ratios within the training dataset (Methods). 95% confidence intervals for the area under the curve
- 267 (AUC) on the holdout dataset were estimated via bootstrapping (Methods).

### 269 Supplementary Table 19. Stratified holdout performance assessment for a COVID-19

270 susceptibility model built from age, sex, and exposures (Dem + Exp)

271

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	228	38	190	0.88 (0.82, 0.94)	0.89 (0.80, 0.99)	0.65 (0.59, 0.72)
All	4834	632	4202	0.84 (0.82, 0.86)	0.75 (0.72, 0.79)	0.76 (0.75, 0.78)
European Genetic Ancestry	3372	408	2964	0.84 (0.82, 0.87)	0.74 (0.70, 0.78)	0.79 (0.77, 0.80)
Admixed Amerindian Genetic Ancestry	410	73	337	0.80 (0.74, 0.86)	0.74 (0.64, 0.84)	0.71 (0.66, 0.75)
Other Genetic Ancestry	824	113	711	0.83 (0.78, 0.87)	0.77 (0.69, 0.85)	0.71 (0.68, 0.75)
Ages 18-29	340	74	266	0.83 (0.77, 0.89)	0.81 (0.72, 0.90)	0.65 (0.59, 0.71)
Ages 30-49	1744	270	1474	0.80 (0.77, 0.83)	0.82 (0.77, 0.86)	0.59 (0.56, 0.61)
Ages 50-65	1515	200	1315	0.85 (0.82, 0.88)	0.73 (0.67, 0.79)	0.81 (0.79, 0.83)
Ages 65+	1235	88	1147	0.81 (0.75, 0.87)	0.57 (0.47, 0.67)	0.96 (0.95, 0.97)
Female	3354	409	2945	0.83 (0.81, 0.85)	0.73 (0.68, 0.77)	0.77 (0.75, 0.79)
Male	1480	223	1257	0.85 (0.82, 0.88)	0.81 (0.76, 0.86)	0.75 (0.73, 0.77)

272

Case/control status is defined based on a self-reported COVID-19 positive test result. The Dem +
 Exp model includes questions about exposures, age, and sex (Supplementary Table 18). Metric

performance columns reflect mean and nominal 95% confidence intervals for each metric on an
 internal, independent holdout dataset (Methods). Cohort-level receiver operator characteristic
 (ROC) curves were constructed from predicted class probabilities of models trained on the entire

training dataset (Methods).

#### 281 Supplementary Table 20. Stratified holdout performance assessment for a COVID-19

susceptibility model built from age, sex, exposures, and symptoms (Dem + Exp + Symp)

283

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	96	12	84	0.96 (0.88, 1.00)	0.91 (0.75, 1.00)	0.92 (0.86, 0.98)
All	2047	229	1818	0.94 (0.92, 0.96)	0.85 (0.80, 0.89)	0.91 (0.90, 0.93)
European Genetic Ancestry	1457	146	1311	0.93 (0.90, 0.96)	0.83 (0.77, 0.90)	0.91 (0.90, 0.93)
Admixed Amerindian Genetic Ancestry	155	23	132	0.98 (0.95, 1.00)	0.96 (0.87, 1.00)	0.89 (0.84, 0.95)
Other Genetic Ancestry	339	48	291	0.94 (0.90, 0.99)	0.81 (0.70, 0.92)	0.93 (0.90, 0.96)
Ages 18-29	132	29	103	0.98 (0.95, 1.00)	0.93 (0.84, 1.00)	0.92 (0.87, 0.97)
Ages 30-49	582	77	505	0.96 (0.95, 0.98)	0.89 (0.82, 0.96)	0.88 (0.85, 0.91)
Ages 50-65	616	83	533	0.93 (0.90, 0.97)	0.84 (0.76, 0.92)	0.91 (0.88, 0.93)
Ages 65+	717	40	677	0.89 (0.83, 0.96)	0.72 (0.58, 0.86)	0.95 (0.93, 0.97)
Female	1380	139	1241	0.94 (0.91, 0.97)	0.86 (0.80, 0.92)	0.91 (0.89, 0.92)
Male	667	90	577	0.94 (0.90, 0.97)	0.83 (0.76, 0.91)	0.93 (0.91, 0.96)

284

Case/control status is defined based on self-reported COVID-19 positive test result. The Dem +
Exp + Symp model includes questions about exposures, age, sex, and five symptom questions
(Supplementary Table 18). Metric performance columns reflect mean and nominal 95%
confidence intervals for each metric on an internal, independent holdout dataset (Methods).
Cohort-level receiver operator characteristic (ROC) curves were constructed from predicted class
probabilities of models trained on the entire training dataset (Methods).

291

292

# 294 Supplementary Table 21. Stratified holdout performance assessment for a literature-based

#### 295 COVID-19 susceptibility model based on two exposures and one symptom (HWF Exp + 296 Symp)

290

#### 297

298

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	96	12	84	0.94 (0.84, 1.00)	0.92 (0.76, 1.00)	0.94 (0.89, 0.99)
All	2047	229	1818	0.90 (0.88, 0.93)	0.78 (0.73, 0.83)	0.94 (0.93, 0.95)
European Genetic Ancestry	1457	146	1311	0.89 (0.86, 0.92)	0.75 (0.68, 0.82)	0.94 (0.93, 0.95)
Admixed Amerindian Genetic Ancestry	155	23	132	0.94 (0.88, 1.00)	0.87 (0.73, 1.00)	0.92 (0.87, 0.97)
Other Genetic Ancestry	339	48	291	0.92 (0.87, 0.97)	0.79 (0.68, 0.90)	0.96 (0.94, 0.98)
Ages 18-29	132	29	103	0.92 (0.85, 0.99)	0.79 (0.65, 0.94)	0.96 (0.92, 1.00)
Ages 30-49	582	77	505	0.91 (0.86, 0.95)	0.82 (0.73, 0.91)	0.92 (0.90, 0.95)
Ages 50-65	616	83	533	0.91 (0.87, 0.95)	0.81 (0.73, 0.89)	0.93 (0.91, 0.95)
Ages 65+	717	40	677	0.85 (0.77, 0.92)	0.65 (0.50, 0.80)	0.96 (0.95, 0.98)
Female	1380	139	1241	0.91 (0.88, 0.94)	0.81 (0.75, 0.88)	0.94 (0.92, 0.95)
Male	667	90	577	0.89 (0.85, 0.94)	0.73 (0.64, 0.83)	0.95 (0.94, 0.97)

299 Case/control status is defined based on self-reported COVID-19 positive test result. The literature-300 based HWF Exp + Symp model contains two exposure questions and a question about one

301 symptom (change in taste or smell, Supplementary Table 18).[18] Metric performance columns

302 reflect mean and nominal 95% confidence intervals for each metric on an internal, independent 303 holdout dataset (Methods). Cohort-level receiver operator characteristic (ROC) curves were 304 constructed from predicted class probabilities of models trained on the entire training dataset 305 (Methods).

306

307

308

309

### 311 Supplementary Table 22. Stratified holdout performance assessment for a literature-based

312 COVID-19 susceptibility model based on seven symptoms (HWF Symp)

- 313
- 314

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	96	12	84	0.90 (0.77, 1.00)	0.84 (0.62, 1.00)	0.92 (0.86, 0.98)
All	2047	229	1818	0.87 (0.84, 0.90)	0.75 (0.69, 0.80)	0.91 (0.90, 0.93)
European Genetic Ancestry	1457	146	1311	0.87 (0.83, 0.91)	0.75 (0.68, 0.82)	0.91 (0.89, 0.93)
Admixed Amerindian Genetic Ancestry	155	23	132	0.92 (0.85, 0.99)	0.87 (0.73, 1.00)	0.93 (0.89, 0.97)
Other Genetic Ancestry	339	48	291	0.83 (0.76, 0.91)	0.67 (0.53, 0.80)	0.92 (0.89, 0.95)
Ages 18-29	132	29	103	0.85 (0.75, 0.96)	0.79 (0.64, 0.95)	0.94 (0.90, 0.99)
Ages 30-49	582	77	505	0.89 (0.85, 0.93)	0.75 (0.66, 0.85)	0.88 (0.85, 0.91)
Ages 50-65	616	83	533	0.86 (0.80, 0.91)	0.75 (0.65, 0.84)	0.89 (0.87, 0.92)
Ages 65+	717	40	677	0.84 (0.76, 0.92)	0.70 (0.55, 0.85)	0.95 (0.93, 0.96)
Female	1380	139	1241	0.87 (0.83, 0.91)	0.76 (0.69, 0.83)	0.90 (0.88, 0.92)
Male	667	90	577	0.87 (0.83, 0.92)	0.73 (0.63, 0.82)	0.94 (0.92, 0.96)

315 Case/control status is defined based on self-reported COVID-19 positive test result. The literature-

316 based HWF Symp model contains 7 symptoms most commonly associated with COVID-19

317 (Supplementary Table 18).[18] Metric performance columns reflect mean and nominal 95%

318 confidence intervals for each metric on an internal, independent holdout dataset (Methods).

319 Cohort-level receiver operator characteristic (ROC) curves were constructed from predicted class

320 probabilities of models trained on the entire training dataset (Methods).

# 322 Supplementary Table 23. Comparison between train and holdout performances for different

## 323 risk models

324

#### 325

Model	Train AUC (95% CI)	Holdout AUC (95% CI)
Susceptibility– no symptoms (Dem + Exp)	0.83 (0.81, 0.85)	0.84 (0.82, 0.84)
Susceptibility- with symptoms (Dem + Exp + Symp)	0.95 (0.93, 0.97)	0.94 (0.92, 0.96)
Susceptibility- literature-based "minimal" model (HWF Exp + Symp)	0.90 (0.88, 0.92)	0.90 (0.88, 0.93)
Susceptibility- literature-based "symptoms-only" model (HWF Symp)	0.87 (0.84, 0.90)	0.87 (0.84, 0.90)
Severity- hospitalization	0.85 (0.82, 0.88)	0.87 (0.84, 0.90)
Severity- critical case of COVID-19	0.90 (0.87, 0.93)	0.90 (0.87, 0.93)

326

327 Columns reflect mean and nominal 95% confidence intervals for the area under the curve (AUC)

328 of trained models on either the training or holdout dataset. Confidence intervals were estimated

329 via bootstrapping (Methods).

#### 331 Supplementary Table 24. Stratified holdout performance assessment for models to predict

#### 332 hospitalization amongst COVID-19 positive cases

333

cohort	N	ncase	ncontrol	Auc	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	110	20	90	0.81 (0.72, 0.90)	0.85 (0.68, 1.00)	0.71 (0.62, 0.80)
All	1793	191	1602	0.87 (0.84, 0.90)	0.83 (0.78, 0.88)	0.75 (0.73, 0.77)
European Genetic Ancestry	1133	120	1013	0.87 (0.84, 0.90)	0.82 (0.76, 0.89)	0.74 (0.72, 0.77)
Admixed Amerindian Genetic Ancestry	219	16	203	0.94 (0.90, 0.98)	0.93 (0.81, 1.00)	0.79 (0.74, 0.85)
Other Genetic Ancestry	331	35	296	0.85 (0.77, 0.93)	0.80 (0.67, 0.94)	0.75 (0.70, 0.80)
Ages 18-29	201	7	194	0.95 (0.91, 0.99)	0.85 (0.57, 1.00)	0.90 (0.85, 0.94)
Ages 30-49	705	49	656	0.87 (0.82, 0.93)	0.76 (0.63, 0.88)	0.85 (0.82, 0.88)
Ages 50-65	616	78	538	0.86 (0.81, 0.90)	0.86 (0.78, 0.94)	0.65 (0.61, 0.69)
Ages 65+	271	57	214	0.78 (0.72, 0.85)	0.86 (0.77, 0.95)	0.53 (0.47, 0.60)
Female	1166	118	1048	0.87 (0.83, 0.90)	0.80 (0.72, 0.87)	0.77 (0.74, 0.79)
Male	627	73	554	0.87 (0.83, 0.91)	0.89 (0.82, 0.96)	0.71 (0.67, 0.75)

334

335 Case/control status is defined based on self-reported hospitalization due to COVID-19-related 336 illness (Methods). Metric performance columns reflect mean and nominal 95% confidence 337 intervals for each metric on an internal, independent holdout dataset (Methods). Cohort-level 338 receiver operator characteristic (ROC) curves were constructed from predicted class probabilities 339 of models trained on the entire survey cohort (Methods).

### 342 Supplementary Table 25. Stratified holdout performance assessment for models to predict

#### 343 critical COVID-19 cases amongst all COVID-19 positive cases

344

cohort	N	ncase	ncontrol	AUC	Sensitivity	Specificity
Admixed African-European Genetic Ancestry	110	15	95	0.87 (0.78, 0.97)	0.93 (0.80, 1.00)	0.75 (0.66, 0.83)
All	1793	105	1688	0.90 (0.87, 0.93)	0.93 (0.87, 0.98)	0.79 (0.77, 0.81)
European Genetic Ancestry	1133	70	1063	0.90 (0.86, 0.93)	0.90 (0.83, 0.97)	0.79 (0.76, 0.81)
Admixed Amerindian Genetic Ancestry	219	7	212	0.92 (0.88, 0.96)	1.00 (0.60, 1.00)	0.83 (0.78, 0.88)
Other Genetic Ancestry	331	13	318	0.92 (0.87, 0.97)	1.00 (0.73, 1.00)	0.77 (0.73, 0.82)
Ages 18-29	201	2	199	0.96 (0.92, 0.99)	1.00 (0.29, 1.00)	0.92 (0.88, 0.96)
Ages 30-49	705	24	681	0.94 (0.92, 0.96)	1.00 (0.84 1.00)	0.84 (0.81, 0.87)
Ages 50-65	616	43	573	0.87 (0.82, 0.93)	0.91 (0.82, 0.99)	0.71 (0.68, 0.75)
Ages 65+	271	36	235	0.84 (0.78, 0.91)	0.89 (0.78, 0.99)	0.71 (0.66, 0.77)
Female	1166	60	1106	0.90 (0.86, 0.94)	0.93 (0.87, 1.00)	0.80 (0.77, 0.83)
Male	627	45	582	0.89 (0.85, 0.93)	0.91 (0.83, 0.99)	0.77 (0.73, 0.80)

345


346 Case/control status is defined based on self-reported critical case progression among all COVID-

19 cases. Here, a critical case is defined based on self-reported ICU admittance, respiratory failure,
organ failure, or septic shock resulting from COVID-19-related illness (Methods). Metric
performance columns reflect mean and nominal 95% confidence intervals for each metric on an
internal, independent holdout dataset (Methods). Cohort-level receiver operator characteristic
(ROC) curves were constructed from predicted class probabilities of models trained on the entire
survey cohort (Methods).


353

354

#### **356 SUPPLEMENTARY FIGURES**




358 Supplementary Figure 1. Severity (critical case) odds ratios (ORs) and 95% confidence 359 intervals (CIs) estimated from simple ("Unadjusted models," grey) and multiple ("Adjusted 360 models," black) logistic regression with adjustment for other risk factors. Open circles 361 indicate not significant (p-value > 0.05) after accounting for multiple hypothesis tests using 362 Bonferroni correction. Age, sex, genetic ancestry, and obesity ORs were estimated in relation to 363 the reference variables indicated. Exposure, health, and symptom ORs were each estimated 364 separately as binary variables. Symptom ORs were estimated as binary variables among 365 symptomatic testers only (Methods). Risk factor adjustments for severity include: sex, age, obesity 366 (Y/N), and underlying health conditions (Y/N if any). Where applicable, individual adjustment 367 variables were omitted to avoid duplicate adjustment (Methods).




#### 370 Supplementary Figure 2. Comparison of Susceptibility and Severity adjusted ORs.

- 371 Comparison of susceptibility ORs (horizontal axis) and severity ORs (vertical axis) from Figures
- 372 1 and 2. Severity aORs are for hospitalization. aORs are adjusted as in Figures 1 and 2 (see Figure
- 373 3 for adjusted ORs for symptoms). Plotted on a log scale for visibility. A) **Demographics**, broken
- down by age, sex, and genetic ancestry. B) Health conditions: Some pre-existing health
- 375 conditions have increased odds of critical outcomes but susceptibility is not characterized by health
- 376 conditions. C) **Exposures** are important for susceptibility but not severity.
- 377




378 379 Supplementary Figure 3. Risk model confusion matrices for independent holdout data. 380 Numbers represent number of individuals in each category. A) Susceptibility model with 381 demographics, exposures, and symptoms. B) Susceptibility model demographics and exposures (symptoms excluded). C) Literature-based susceptibility model with three risk factors including 382 383 two exposures and change in taste or smell. D) Literature-based susceptibility model with seven 384 COVID-19 symptoms. E) Hospitalization risk model. F) Critical case risk model. Refer to Methods 385 as well as Supplementary Tables 18-25 for additional model performance data and model risk 386 factor information.





Supplementary Figure 4. Performance of susceptibility models evaluated in a symptomatic cohort of positive and negative testers. Plot depicts receiver operating characteristic (ROC) curves for four susceptibility models (Supplementary Table 18). Here, the modeling cohort has been restricted to positive and negative testers reporting at least one symptom of moderate or greater intensity for model training and evaluation.





Supplementary Figure 5. Concordance between the EGA cohort and AncestryDNA cohort (V3) from this study. A) Concordance of susceptibility associations between the EGA dataset (vertical axis) and the AncestryDNA dataset from this study (V3, horizontal axis), plotted as log mean effect estimates (logORs). B) Concordance of hospitalization associations between the EGA dataset (vertical axis) and the AncestryDNA dataset from this study (V3, horizontal axis). C)

401 Independent holdout performance of susceptibility models trained within the EGA dataset. D)

402 Independent holdout performance of severity models trained within the EGA dataset.

403

404

405